

1 Gut microbiota modulates distal symmetric polyneuropathy in 2 diabetic patients

3 **Authors:** Junpeng Yang^{1*}, Xueli Yang^{1*}, Guojun Wu^{2,3*}, Fenglian Huang¹, Xiaoyang Shi¹, Wei Wei¹,
4 Yingchao Zhang¹, Haihui Zhang⁴, Lina Cheng⁴, Lu Yu¹, Jing Shang¹, Yinghua Lv¹, Xiaobing Wang¹, Rui
5 Zhai², Pan Li^{5,6}, Bota Cui^{5,6}, Yuanyuan Fang¹, Xinru Deng¹, Shasha Tang¹, Limin Wang¹, Qian Yuan¹,
6 Liping Zhao^{2,3†}, Faming Zhang^{5,6†}, Chenhong Zhang^{2†}, Huijuan Yuan^{1†}

7 8 Affiliations

9 ¹ Department of Endocrinology, Henan Provincial Key Medicine Laboratory of Intestinal Microecology
10 and Diabetes, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou,
11 Henan, 450003, P.R. China.

12 ² State Key Laboratory of Microbial Metabolism and Ministry of Education Key Laboratory of Systems
13 Biomedicine, Rutgers-SJTU Joint Laboratory on Microbiome and Human Health, School of Life Sciences
14 and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.

15 ³ Department of Biochemistry and Microbiology and New Jersey Institute for Food, Nutrition, and Health,
16 School of Environmental and Biological Sciences, Rutgers University, NJ, 08901, USA.

17 ⁴ Department of Gastroenterology of Henan Provincial People's Hospital, People's Hospital of Zhengzhou
18 University, Zhengzhou, Henan, 450003, P.R. China.

19 ⁵ Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University,
20 Nanjing, 210011, P.R. China.

21 ⁶ Key Laboratory of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, P.R.
22 China.

23 *These authors contributed equally to this work.

24 †Corresponding authors: Huijuan Yuan, e-mail: hjyuan@zzu.edu.cn

25 Chenhong Zhang, e-mail: zhangchenhong@sjtu.edu.cn

26 Faming Zhang, e-mail: fzhang@njmu.edu.cn

27 Liping Zhao, e-mail: lpzhao@sjtu.edu.cn, liping.zhao@rutgers.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 **SUMMARY**

29 The contribution of the gut microbiota to distal symmetric polyneuropathy (DSPN) in diabetic
30 patients remains elusive. We found that the gut microbiota from DSPN patients induced more
31 severe peripheral neuropathy in db/db mice. Gut microbiota from healthy donors significantly
32 alleviated DSPN independent from glycaemic control in patients in a randomized, double-
33 blind and placebo-controlled trial. The gut bacterial genomes correlated with Toronto Clinical
34 Scoring System score were organized in two competing guilds. Increased Guild 1 that had
35 higher capacity in butyrate production and decreased Guild 2 that harbored more genes in
36 synthetic pathway of endotoxin were associated with improved gut barrier integrity and
37 decreased proinflammatory cytokine levels. Moreover, matched enterotype between
38 transplants and recipients showed better therapeutic efficacy with more enriched Guild 1 and
39 suppressed Guild 2. Thus, the two competing guilds may mediate the causative role of the gut
40 microbiota in DSPN and have the potential to be an effective target for treatment.

41 **INTRODUCTION**

42 As the most common neuropathy in patients with diabetes mellitus (DM),
43 distal symmetric polyneuropathy (DSPN) is a pernicious unmet medical need, which affects
44 approximately half of the diabetic patients including both type1 and type 2 diabetes mellitus
45 (T1DM and T2DM) (Hicks and Selvin, 2019; Sloan et al., 2021). DSPN is associated with
46 increased mortality, lower-limb amputations and distressing painful neuropathic symptoms,
47 which negatively affect patients' functionality, mood, and health-related quality of life (Li et
48 al., 2013; Slangen et al., 2014). Although lifestyle modification, glucose control and a few
49 medications may ameliorate the symptoms in some patients with DSPN, no disease-
50 modifying treatments for DSPN are available due to the paucity of understanding of its

51 underlying pathogenetic mechanism and lack of effective targets (Pop-Busui et al., 2017;
52 Sloan et al., 2021).

53 Compelling and converging evidence show a causative role of gut microbiota in
54 maintaining the glucose homeostasis (de Groot et al., 2020; Metwaly et al., 2022; Sanna et al.,
55 2019; Tang et al., 2022; Zhao et al., 2018). The gut microbiota may also function at the
56 intersection between the gut-brain and the neuroimmune-endocrine axes, forming a complex
57 network that can affect the nervous system (Fung et al., 2017; Pane et al., 2022). Increasingly,
58 studies have demonstrated that the cross-talk between the gut microbiota and brain may
59 crucially impact neurodegenerative disorders of the central nervous system, such as in
60 Parkinson's and Alzheimer's diseases (Bulgart et al., 2020; Tansey et al., 2022). In addition,
61 the gut microbiota and its bioactive substances are known to regulate host bioenergetics and
62 inflammation, possible mechanistic pathways of DSPN (Bonhof et al., 2019; Thevaranjan et
63 al., 2017; Tilg et al., 2020). Recently, a cohort study with small sample size showed that the
64 gut microbiota of patients with DSPN was different from healthy control (Wang et al., 2020).
65 However, the causative relationship between the gut microbiota and peripheral nervous
66 system disorders in DM remains elusive.

67 Fecal microbiota transplantation (FMT) from healthy donors to the gut of patients and/or
68 from patients to mice has become a powerful strategy to demonstrate if the gut microbiota
69 may play a causative role in a particular pathology such as DSPN (Hanssen et al., 2021;
70 Sorboni et al., 2022). Here, we found significant differences of the gut microbiota among the
71 subjects with normal glucose level and DM patients with or without DSPN. Furthermore, we
72 showed that the fecal microbiota from patients with DSPN induced more serious peripheral
73 neuropathy than the subjects with normal glucose level by inoculating the fecal microbiota to
74 the db/db mice, suggesting that dysbiosis of gut microbiota contributes to the progression of

75 DSPN. Then we performed FMT from healthy donors to DSPN patients who responded
76 poorly to conventional treatments in a randomized, double-blind, placebo-controlled pilot
77 clinical trial. The results showed that modulation of the composition and function of gut
78 microbiota via FMT from healthy donors induced significant alleviation of DSPN. This study
79 revealed a potentially causative link between the gut microbiota and peripheral nervous
80 system disorders in DM, which could become a therapeutic target for developing effective
81 treatment.

82 **RESULTS**

83 *The gut microbiota from patients with DSPN induced more severe peripheral neuropathy in* 84 *db/db mice*

85 We collected fecal samples from the DM patients with DSPN (DSPN, n = 27), and compared
86 their gut microbiota with that in DM patients without DSPN (DM, n = 30) and subjects with
87 normal glucose level (NG, n = 29) from our previous dataset (Deng et al., 2022; Fang et al.,
88 2021) (Table S1). Based on the sequencing data of V3-V4 regions of 16S rRNA genes, the
89 richness of gut microbiota in patients with DSPN was significantly higher than that in DM
90 and NG groups (Figure S1A). Principal coordinate analysis (PCoA) based on Jaccard distance
91 showed that the overall structure of gut microbiota in DSPN was different from that in DM
92 and NG groups (Figure S1B).

93 Next, to evaluate whether the dysbiosis of gut microbiota contributes to the development
94 of peripheral neuropathy, we transplanted the fecal microbiota from DSPN and NG group to
95 the genetically diabetic mice respectively. After treatment with a cocktail of antibiotics for 2
96 weeks, the db/db mice at 13-weeks old were gavaged with the fecal microbiota either from
97 DSPN (M-DSPN, n = 6) or NG group (M-NG, n = 6). The structure of the gut microbiota in
98 the M-DSPN mice was significantly different from that in M-NG mice ($P = 0.004$ by

99 PerMANOVA test with 999 permutations), and the gut microbiota of the recipient mice was
100 more similar to that of the corresponding human donors (Figure S2). We evaluated the
101 severity of peripheral neuropathy in the mice at the end of third week after FMT. Compared
102 to the M-NG group, the M-DSPN mice showed higher mechanical and thermal sensitivity,
103 which were reflected by the level of 50% threshold and thermal latency, and lower MNCV of
104 sciatic nerve (Figure 1A). The M-DSPN mice also had significant lower intraepidermal nerve
105 fiber density (IENFD) of the posterior plantar skin by immunohistochemistry analysis, which
106 was used to assess the neuropathy in the small fiber (Figure 1B). In the peripheral nervous
107 systems, neurofilament 200 (NF200) was a special marker for A-fibers, myelin basic protein
108 (MBP) was associated with the formation and maintenance of myelin, and brain derived
109 neurotrophic factor (BDNF) was required for survival, proliferation, migration and
110 differentiation of neurons and neurogliaocytes (Fan et al., 2020; Zhang et al., 2019) (McGregor
111 and English, 2018). Previous studies have found that NF200, MBP and BDNF decreased
112 significantly in dorsal root ganglion (DRG) and sciatic nerve when peripheral nerve injured
113 by diabetes (Fan et al., 2020; Zhang et al., 2019). The levels of these three proteins were
114 significantly lower in M-DSPN mice than M-NG group both in DRG and sciatic nerve
115 (Figure 1C and D). The above results suggest that the gut microbiota from patients with
116 DSPN aggravates peripheral neuropathy in db/db mice.

117 We also assessed the effects of gut microbiota from patients with DSPN on the gut
118 barrier function. The immunofluorescence staining showed that the expression of the tight
119 junction proteins ZO-1, Claudin-1 and Claudin-4 in the colonic mucosal biopsy specimens
120 were significantly lower in M-DSPN mice than that in M-NG group (Figure 1E), indicating
121 worse gut barrier function in M-DSPN mice. Then we tested the serum level of
122 lipopolysaccharide (LPS)-binding protein (LBP), which can bind to antigens such as
123 endotoxin produced by bacteria and represent a surrogate biomarker that links bacterial

124 antigen load in the blood and the host inflammatory response. Notably, the level of LBP was
125 significantly higher in the M-DSPN mice than that in M-NG group (Figure 1F). We assessed
126 the inflammatory status of the mice. Indeed, the serum levels of TNF- α and IL-6, which are
127 systemic inflammation biomarkers that have been associated with DSPN progression
128 (Feldman et al., 2017; Herder et al., 2017), were higher in the M-DSPN mice than that in M-
129 NG group (Figure 1F). These results suggest that gut barrier dysfunction, higher antigen load
130 and severer systemic inflammation may contribute to the aggravation of peripheral
131 neuropathy by the gut microbiota from patients with DSPN.

132 ***FMT alleviated the severity of peripheral neuropathy in patients with DSPN***

133 As the dysbiosis of gut microbiota contributed to the development of peripheral neuropathy,
134 we would like to find out whether improvement of gut microbiota can alleviate DSPN in
135 patients. Thirty-seven DSPN patients were randomized into either FMT or placebo group in a
136 2:1 ratio. Before enrolment into this trial, all patients showed no improvement in their DSPN
137 symptoms after at least 84 days of conventional treatments (lifestyle modification, glucose
138 control and drug intervention, medical details in Table S2). After the run-in period, these
139 patients were transplanted with transplants made from fecal microbiota of the healthy donors
140 or placebo and then were followed up for 84 days. Finally, 22 patients in the FMT group and
141 10 patients in the placebo group completed this RCT study (Figure S3). At baseline (0D),
142 demographic and anthropometric characteristics and glycemetic control were similar between
143 the two groups (Table S3). In particular, there were no significant differences in the level of
144 Toronto Clinical Scoring System (TCSS (Arumugam et al., 2016)) score and the sensory and
145 motor nerve functional status of DSPN (Figure 2 and Figure S4). At 84 days after
146 transplantation (84D), glucose and lipid metabolism, blood pressure and body weight
147 remained unchanged in both groups (Table S3). The insulin requirement was similar between

148 the two groups (Table S3) and no serious adverse events were documented during the trial
149 (Table S4).

150 TCSS score is used to evaluate the neuropathic symptoms and signs of patients, as the
151 standard to assess the severity of DSPN (Arumugam et al., 2016). We used the change of
152 TCSS score at 84D compared with baseline as the primary outcome and the results showed
153 that the reduction of TCSS score was significantly greater in the FMT group than that in the
154 placebo group (Figure 2A). Moreover, the levels of TCSS at 84D for the patients subjected to
155 FMT were significantly lower than baseline, but no changes were observed in the placebo
156 group, and the levels of TCSS in the FMT group were significantly lower than that in the
157 placebo group at 84D (Figure 2A). We also evaluated neuropathic pain of the patients with
158 visual analogue scale (VAS (Petersen et al., 2021)) score. Compared to baseline, the VAS
159 scores also decreased significantly after FMT, but not in placebo group. The levels of VAS
160 were significantly lower than that in the placebo group at 84D (Figure 2B). Notably, fifteen
161 patients in the FMT group, who suffered from moderate/severe neuropathic pain (VAS score
162 ≥ 4) at baseline and eight of them (53.3%) had more than 50% pain relief at 84D as compared
163 with baseline, which was considered a good outcome (Petersen et al., 2021) . While only
164 14.29% patients in placebo group showed more than 50% pain relief at 84D, based on the
165 VAS, which was significantly lower than that in FMT group. These results indicate that FMT
166 induced stable relief of the symptoms and signs, particularly the neuropathic pain, in the
167 patients with DSPN.

168 As the neuropathic symptoms severely induce anxiety, depression, sleep disorders and
169 reduce the quality of life in DSPN patients (Gylfadottir et al., 2020), we assessed the effects
170 of FMT on anxiety, depression, sleep quality and overall quality of life by using the Hamilton
171 Anxiety Scale (HAMA (Zhao et al., 2021)), Hamilton Depression Rating Scale (HAMD

172 (Zhao et al., 2021)), Pittsburgh Sleep Quality Index (PSQI (Buysse et al., 1989)) and the Brief
173 table of the World Health Organization's Quality of Life (WHOQOL-BREF (Saxena et al.,
174 2001)). After 84 days of transplantation, HAMA and HAMD score showed that the anxiety
175 and depression status were significantly improved in the FMT group but not in the placebo
176 group (Figure 2C and D). PSQI assessment showed that sleep quality was significantly
177 improved in patients subjected to FMT at 84D but not in those that received the placebo
178 (Figure 2E). The WHOQOL-BREF score significantly increased in both FMT and placebo
179 groups at 84D, suggesting improved quality of life for all the patients (Figure 2F).

180 We used electrophysiological measurements (nerve conduction velocity (NCV) and
181 current perception threshold (CPT)) to objectively assess whether FMT improve peripheral
182 neuropathy (Dyck et al., 1997). At 84 days after transplantation, the sensory nerve conduction
183 velocities (SNCVs) of sural nerves and ulnar nerves were significantly increased only in
184 patients of the FMT group and the changes of SNCVs were significantly greater in the FMT
185 group than in the placebo group (Figure S4A-C). The motor nerve conduction velocities
186 (MNCVs) of the distal median nerves, posterior tibial nerves and common peroneal nerve
187 were significantly improved in patients of the FMT group but not in placebo (Figure S4D-G).
188 CPT can be used to visualize the sensitivity of different types of never fibers to electrical
189 stimulation, including the thick myelinated ($A\beta$) fibers (2000Hz), thin myelinated ($A\delta$) fibers
190 (250Hz), and unmyelinated (C) fibers (5Hz) (Lv et al., 2015). For superficial and deep
191 peroneal nerve, the CPT level at 5 Hz was significantly decreased in FMT group after 84
192 days, and significantly lower in FMT group than that in placebo group, indicating that the
193 hypoesthesia of C-fibers in legs of FMT group improved (Figure S4H-J). For distal median
194 nerve, the CPT levels at 2000Hz, 250Hz and 5Hz all decreased significantly in FMT group
195 but not in placebo after 84 days, and the changes at 250Hz and 5Hz were significantly greater
196 in the FMT group than in the placebo group, suggesting that FMT may influence on $A\beta$, $A\delta$

197 and C nerve fibers of distal upper limbs (Figure S4K-M). This suggests that introduction of
198 gut microbiota from healthy donors improved the electrophysiological functions of peripheral
199 nerves in patients with DSPN.

200 After finishing the RCT study, to further verify the alleviation of neuropathic symptoms
201 and signs in patients with DSPN by FMT, we transplanted the transplants made from fecal
202 microbiota of the healthy donors to all of the ten patients in placebo group (post-RCT study).
203 Compared to the baseline or the end of the RCT study, these patients showed significantly
204 improvement of the neuropathic symptoms and signs, anxiety status, sleep quality, overall
205 quality of life, and electrophysiological functions of peripheral nerves after 84 days of
206 transplantation with the transplants from healthy donors (Figure S5 and S6).

207 ***FMT improved gut barrier integrity and systemic inflammatory status in patients with***
208 ***DSPN***

209 As we had found that the dysbiosis gut microbiota from the patients with DSPN made damage
210 of gut barrier in the aforementioned db/db mice study, in order to find out whether FMT, the
211 gut microbiota – targeted treatment, could improve gut barrier function and decrease chronic
212 inflammation of the patients, we collected biopsy specimens of colon from part of our patients
213 at baseline and 84 days after transplantation in RCT study. The immunofluorescence staining
214 showed that the expression of the tight junction proteins ZO-1 and Claudin-1 in the colonic
215 mucosa of biopsy specimens were significantly higher in FMT than that in placebo group at
216 84D (Figure 3A and B). In addition, Claudin-4 was promoted in specimens from patients in
217 both FMT and placebo group, but the changes were significantly greater in the FMT group
218 (Figure 3C).

219 Because the improvement of the gut barrier integrity would decrease the serum antigen
220 load from microbiota, we tested the serum level of LBP, and found that the level of LBP was
221 significantly reduced in the FMT group but not in the placebo group (Figure 3D). Then we
222 assessed the inflammatory status of patients with DSPN after FMT. Indeed, the serum levels
223 of IL-6 and TNF- α decreased in the FMT group at 84D but did not change in the placebo
224 group (Figure 3E and F). This suggests that FMT improved the gut barrier function, reduced
225 serum antigen load and aforementioned alleviation of chronic inflammation, which may
226 contribute to alleviate DSPN in patients.

227 ***FMT induced overall structural changes in the gut microbiota in patients with DSPN***

228 To further explore the role of gut microbiota in the beneficial effect on DSPN alleviation via
229 FMT, we did shotgun metagenomic sequencing of all the transplants made from gut
230 microbiota of the donors, and the fecal samples from all the patients in the RCT study and
231 post-RCT study before transplantation (0D), 3 days (3D), 28 days (28D), 56 days (56D), and
232 84 days (84D) after transplantation (Table S5). To characterize the strain-level changes in the
233 gut microbiota in patients following FMT, we *de novo* assembled 1,572 high-quality draft
234 genomes from the metagenomic dataset (details in Materials and Methods, Table S6 and S7).
235 After integrating the genomes from Human Gastrointestinal Bacteria Genome Collection
236 (HGG) (Forster et al., 2019) to improve the metagenomic analysis, 1,999 non-redundant high-
237 quality metagenome-assembled genomes (HQMAGs) were obtained and used in the further
238 analysis (Table S8). Transplantation with placebo showed no significant alteration in the gut
239 microbiota in the patients during the RCT study (Figure S7). Then samples from the FMT
240 group in RCT study and sample from the post-RCT study together with transplants from
241 healthy donors were analyzed to reveal the alteration in gut microbiota during FMT. To
242 determine probable microbial origins in longitudinal samples after FMT, unique HQMAGs

243 detectable in pre-FMT patient (0D) samples and FMT transplants were compared (Figure
244 4A). The relative abundance of HQMAGs only detected in the FMT transplants only
245 accounted for 48.1% of the HQMAGs shared between the 0D samples of patients and
246 corresponding transplants. Transplant-derived HQMAGs accounted for a considerable
247 proportion of the population from day 3 to day 84 after FMT (3D to 84D). The distance
248 between the patient's gut microbiota and that of corresponding transplants was significantly
249 decreased after FMT, although the gut microbiota structures in the patients were still closer to
250 each individual's own baseline composition than to the transplants (Figure 4B). There was a
251 significant increase in richness of the gut microbiota at 28D after FMT, but the diversity
252 measured by Shannon index was not altered (Figure 4C). Subject adjusted principal
253 coordinate analysis (aPCoA) of Jaccard distances at the HQMAGs level demonstrated that the
254 gut microbiome of patients significantly shifted after 3 days of FMT (3D). The gut
255 microbiome further significantly changed after 28 days (28D) and remained relative stable
256 afterward (56D-84D) (Figure 4D). These results suggest that FMT induced early and
257 significant alterations in the gut microbiota of DSPN patients, which were concomitant with
258 significant and stable improvement of neuropathic symptoms and signs.

259 ***The gut microbial genomes correlated with TCSS score were organized in two competing***
260 ***guilds***

261 Next, we identified that TCSS scores were significantly correlated with 54 HQMAGs (Figure
262 5A and Table S9), among which 21 and 33 HQMAGs had negative and positive correlations,
263 respectively, by using linear mixed effect model via MaAsLin2 (Mallick et al., 2021). Most of
264 the HQMAGs (19 of 21) negatively correlated with TCSS score were belonged to Firmicutes,
265 and many of them are potentially beneficial bacteria that can regulate mucosal barrier function
266 to reduce gut permeability and/or modulate the host immune response, possibly via

267 production of butyrate (Cani et al., 2022; Derrien et al., 2022; Gomes et al., 2018; Li et al.,
268 2019; Maioli et al., 2021; Waters and Ley, 2019), such as *Fecalibacterium prausnitzii*,
269 *Agathobacter rectalis*, *Agathobaculum butyriciproducens* and *Anaerobutyricum hallii*. Out of
270 the 33 HQMAGs positively correlated with TCSS score, 26 were belonged to Bacteroidetes,
271 in especial 17 from *Bacteroides uniformis*. As bacteria in the gut ecosystem interact with each
272 other and work as coherent functional groups (a.k.a “guilds”) (Wu et al., 2021), we applied
273 co-abundance analysis on these 54 HQMAGs to explore the interactions between them and to
274 find potential guilds structure. The 54 HQMAGs were organized into two guilds-the 21
275 HQMAGs negatively correlated with TCSS score were positively interconnected with each
276 other and formed as Guild 1, which was true for the 33 HQMAGs positively correlated with
277 TCSS score as Guild 2 (Figure 5B). There were only negative correlations between the two
278 guilds, suggesting a potentially competitive relationship between the two guilds. We found
279 that the abundance of Guild 1 was almost equal to Guild 2 in the gut microbiota of transplants
280 from healthy donors, but the abundance of Guild 2 was significantly higher than Guild 1 in
281 the patients with DSPN at baseline (Figure 5C). Compared to their transplants, the gut
282 microbiota of patients with DSPN contained significantly much more Guild 2 and slightly
283 fewer Guild 1 (Figure 5C). Notably, FMT significantly decreased the abundance of Guild 2
284 and mildly increased the abundance of Guild 1 from 3D, and there was no significant
285 difference between Guild 1 and 2 from 28D to 84D (Figure 5C).

286 Then we studied the genomic features of the two guilds to understand the potential
287 functions underlying their associations with the alleviation of DSPN (Table S9). The SCFAs,
288 derived from gut bacterial fermentation, have been considered as the most important bacterial
289 metabolites affecting gut permeability and regulate intestinal and systemic inflammation in
290 humans (Koh et al., 2016). We used the abundances of genes that encode key enzymes to
291 indicate changes in the SCFAs genetically producing capacity (including acetic acid,

292 propionate, and butyric acid) production pathways (Claesson et al., 2012). Most of the 54
293 HQMAGs carried *fhs* gene involved in the acetic acid biosynthesis pathway, regardless of the
294 Guilds they belonged to (Table S9). For genes encoding the key enzyme propionyl-
295 CoA:succinate-CoA transferase and propionate CoA transferase (*pst* and *pct*) in the
296 propionate synthetic pathway, which has been reported to be negatively associated with
297 glycemic control (Sanna et al., 2019; Tirosh et al., 2019), significantly much more HQMAGs
298 in Guild 2 than that in Guild 1 harbored *pst* or *pct* (*pst*: 14.29 in Guild 1 vs 78.79% in Guild2,
299 Fisher's exact test $P = 4.01 \times 10^{-6}$; *pct*: 23.81% in Guild 1 vs 78.79% in Guild 2, Fisher's exact
300 test $P = 1.59 \times 10^{-4}$) (Figure 5D and Table S9). Conversely, only the HQMAGs in Guild 1 had
301 *but* and *buk* genes, which are the predominate terminal genes for the butyrate biosynthetic
302 pathways in gut microbiota (Figure 5D and Table S9). Moreover, we also assessed the change
303 in endotoxin (LPS) biosynthesis, which is the major antigen from the gut microbiome. Lipid
304 A, the amphipathic LPS glycolipid moiety, stimulates the immune system by tightly binding
305 to Toll-like receptor 4 (Zhang et al., 2021). We showed that most of the HQMAGs in Guild 2
306 (78.79%) carried the genes related to Lipid A biosynthesis, but only two HQMAG in Guild 1
307 had these genes (Figure 5D and Table S9). In terms of antibiotic resistance genes (ARGs), 8
308 HQMAG s in Guild 1 encoded 14 ARGs and 29 genomes in Guild 2 encoded 112 ARGs
309 (Figure 5D and Table S9). Taken together, FMT induced increase of Guild 1 that had the
310 beneficial capacity for butyrate production and decrease of Guild 2 that could produce more
311 antigen load, which contribute to the reduced low-grade, systemic and chronic inflammation.

312 ***Matched enterotype between FMT transplants and recipients linked to better improvement*** 313 ***of DSPN***

314 In the FMT studies, it is always an interesting question whether the resemblance between
315 transplants of gut microbiota from the healthy donors and/or the original gut microbiota in the

316 recipients could be linked to the therapeutic efficacy. Here, we clustered all the samples,
317 including 27 transplants and 150 samples from patients during FMT, into two enterotypes (C1
318 and C2) based on Jaccard distance of their microbiota at HQMAGs-level (Figure 6A). There
319 were 19 transplants and 17 original gut microbiota in the recipients (samples of the patients at
320 0D) classed to C1, and 8 transplants and 15 original gut microbiota in the recipients classed to
321 C2 (Figure 6B). Firstly, in order to test whether the specific transplant enterotype can affect
322 therapeutic efficacy of FMT, we subjected the patients in two subgroups based on enterotypes
323 of the transplants they received. TCSS scores in these two subgroups both showed a
324 significant reduction at 84D after FMT, but there was no significant difference between the
325 two subgroups (Figure S8). Next, we resubjected the patients into transplant-recipient
326 matched or unmatched groups based on whether their original gut microbiota and transplants
327 belonged to the same enterotype. Notably, the abundance of Guild 1 that negatively correlated
328 with TCSS score, was significantly higher in the transplant-recipient matched than that in
329 unmatched group from 56D to 84D after FMT (Figure 6C). Meanwhile, the abundance of
330 Guild 2 that positively correlated with TCSS score, only significantly decreased in transplant-
331 recipient matched group at 3D and kept on lower level from 28D to 84D after FMT, which
332 was significantly lower than that in unmatched group (Figure 6C). Moreover, transplant-
333 recipient matched group had significantly lower TCSS score than unmatched group at 84D
334 (Figure 6D). These results suggest that matched enterotype between transplants and
335 recipients in FMT may introduce better alteration in gut microbiota of the patients and induce
336 better improvement of the symptoms and signs of DSPN.

337 **DISCUSSION**

338 Our study shows that dysbiosis of the gut microbiota in patients contributed to the
339 development of peripheral neuropathy, and modulation of the composition and function of gut

340 microbiota via FMT alleviated neuropathic symptoms and improved sensory and motor nerve
341 function in patients with DSPN.

342 We found the evidence of a causal relationship between the overall gut microbiome and
343 peripheral nervous system disorders via conducting FMT from human to animal and from
344 human to human. Although gut microbiota has been reported to have a role in the
345 pathophysiology of neurological disorders related to enteric nervous system and central
346 nervous system (Cryan et al., 2020; Joly et al., 2021; Morais et al., 2020), the knowledge of
347 the relationship between the gut microbiome and the peripheral nervous disorders is still
348 scanty. Here, we found that compared with control cohorts, patients with DSPN had a distinct
349 gut microbiota composition. Transplanting the gut microbiota from patients with DSPN into
350 the genetically diabetic mice, which received an antibiotic cocktail treatment in advance,
351 induced gut barrier dysfunction, higher antigen load and severer systemic inflammation and
352 aggravated peripheral neuropathy. Moreover, our RCT FMT trial showed that the transplanted
353 gut microbiota from healthy donors was the only trigger for improving the nerve function and
354 neuropathic symptoms in patients with DSPN, indicating a causal role of the gut
355 microbiota (Cartwright, 2011). More importantly, the changes of gut microbiome in patients
356 with DSPN induced by FMT occurred before the alleviation of the symptoms, supporting that
357 the changes in the gut microbiota induced by FMT contributed to the improvement of DSPN
358 rather than a mere consequence after severity had been alleviated.

359 To search for the key bacteria that may mediate the protective effect of the whole gut
360 microbiota in DSPN, we adopted the genome-centric and guild-based approach (Wu et al.,
361 2022; Wu et al., 2021) for analyzing the microbiome data before and after FMT. We did de
362 novo assembly of high-quality genomes from the metagenomic datasets. Using these
363 metagenome-assembled genomes as basic variables allows us to analyze the microbiome data
364 at a resolution much higher than species or any higher taxa (Zhang and Zhao, 2016). We

365 established an ecological network with genomes which were significantly correlated with the
366 primary outcome TCSS score. This allows us to explore how health relevant bacteria in the
367 gut ecosystem interact with each other and form higher level organizations to exert
368 functions(Wu et al., 2021). These genomes turned out to be organized into two competing
369 guilds, one beneficial and one detrimental. The beneficial Guild 1 had much higher genetic
370 capacity in butyrate production and much less genes in synthetic pathway of endotoxin than
371 the detrimental Guild 2. Such a seesaw-like network structure with two competing guilds has
372 been reported as a core microbiome signature associated with various chronic diseases(Wu et
373 al., 2022). Here, FMT effectively increased beneficial Guild 1 and decreased detrimental
374 Guild 2 in the patients with DSPN, leading to a similar abundance of the two guilds to the
375 transplants from healthy donors. Such changes were consistent with the alleviation of DSPN.
376 More importantly, when the transplant and recipient microbiota were of the same enterotype,
377 FMT had better efficacy than the unmatched. Patients receiving transplants with matched
378 enterotype had more increase of Guild 1 and more decrease of Guild 2. This points not only to
379 the mediating role of the two competing guilds in successful FMT but also the importance of
380 the resemblance of the gut microbiota between donor and recipient for improving the
381 therapeutic efficacy of FMT(Holvoet et al., 2021; Kim et al., 2020; Olesen and Gerardin,
382 2021).

383 Our study provides new insights on the potential mechanisms of the effectiveness of
384 FMT in alleviating DSPN. Nerve dysfunction and neuronal cell death in DSPN results from a
385 complex myriad of events that are triggered by the metabolic imbalances associated with
386 diabetes (Feldman et al., 2017), and improvement of glycaemic control and life style are used
387 as conventional treatment to alleviate the symptoms in patients with DSPN. However, glucose
388 and lipid metabolism remained similar between the FMT and control groups of patients
389 throughout our study, suggesting that the alleviations of nerve function and neuropathic

390 symptoms in patients with DSPN after FMT may not be mediated via directly improving
391 glycaemic response. The increased capacity for butyrate production and decreased for
392 endotoxin from the two competing guilds of the gut microbiota may explain the beneficial
393 effect of the gut microbiome after FMT on DSPN. Because reduced production of endotoxin
394 from gut microbiome may reduce antigen load and decrease inflammation (Pan et al., 2018).
395 Butyrate produced by gut microbiota is critical for maintenance of epithelial lining and gut
396 barrier integrity via multiple intracellular processes, including providing essential energy
397 source for colonocytes, activating of the transcription factor hypoxia-inducible factor-1 (HIF-
398 1) to increase the expression of components of intestinal epithelial cell tight junctions,
399 stimulating of mucus production etc. (Xiao et al., 2020). Improved gut barrier function may
400 lead to further reduction of transfer of endotoxin from the gut to the circulation (Pan et al.,
401 2018). More importantly, butyrate is reported to be positively correlated with the pain
402 improvement following FMT and modulate gene expression and immune cells in the
403 peripheral nerve system (PNS) (Bonomo et al., 2020). Though we did not investigate the
404 inflammation in PNS, we found a significant alleviation of systemic inflammation as
405 evidenced by significant decrease of LBP, TNF- α and IL-6 in the patients with DSPN after
406 FMT. In the pathologic process of DSPN, hyperglycaemia, dyslipidaemia, and/or insulin
407 resistance promote activation of the polyol, advanced glycation end products, protein kinase
408 C, poly (ADP-ribose) polymerase, and hexosamine pathways as well as well loss of insulin
409 signaling, which culminates in deleterious effects on mitochondrial function and gene
410 expression along with oxidative stress and inflammation (Dewanjee et al., 2018; Sloan et al.,
411 2021). Among all these complicated pathological changes in both type 1 and type 2 diabetes,
412 systemic inflammation may play a critical role in the development of DSPN. Proinflammatory
413 cytokines not only enhance existing inflammatory and immune responses but also increase
414 cellular oxidative/nitrosative stress, promoting even more neuronal damage in experimental

415 models of DSPN (Schlesinger et al., 2019; Vincent et al., 2013). Systemic inflammation is
416 involved in many complexed metabolic and immune processes and conditions, it is not
417 specific to DSPN. The molecular mechanism of the gut microbiota in the development of
418 DSPN need further investigation.

419 Taking the gut microbiota further into the investigation of DSPN may help us reveal
420 novel mechanisms in its pathogenesis and may provide a new target for developing effective
421 clinical therapies for this common, and pernicious unmet medical need in patients with
422 diabetes mellitus.

423 **ACKNOWLEDGEMENTS**

424 We thank Miao Wang from China Microbiota Transplantation System for offering the WMT
425 and placebo data sources. We acknowledge a computing facility award for use of the Pi
426 cluster at Shanghai Jiao Tong University. This work was supported by the following funding
427 supports: National Natural Science Foundation of China (81970705, 81871091, and
428 31922003).

429 **AUTHOR CONTRIBUTIONS**

430 H. Y., C. Z., F. Z. and L. Z. designed this study. J. Y., X. S., J. S., Y. F., X. D., and S. T.
431 recruited and supervised the participants and performed all clinical procedures. F. H., J. Y.,
432 and X. S. completed the animal experiment. F. Z., P. L. and B. C. provided WMT and the
433 related protocol. W. W., H. Z., L. C., X. W. and Y. L. completed the delivery of FMT. X. Y.,
434 Y. Z., X. W., and Y. L. performed preparation, processing and sequencing of fecal samples.
435 R. Z. analyzed the 16S rRNA sequencing data. G. W., and C. Z. analyzed the metagenomic
436 sequencing data. J. Y., X. Y., X. S., X. W., L. W. and Q. Y. supervised operation of ELISA. C.
437 Z., J. Y. and G. W. performed statistical analysis and generated the figures and tables. C. Z.,

438 H. Y., L. Z., J. Y., X. Y. and G. W. prepared the manuscript. All authors approved the
439 manuscript.

440 **DECLARATION OF INTEREST**

441 Liping Zhao is a co-founder of Notitia Biotechnologies Company.

442 **FIGURES LEGENDS**

443 **Figure 1 | Gut microbiota from patients with DSPN induced more severe peripheral**
444 **neuropathy than that from the subjects with normal glucose level in db/db mice. (A)**
445 Mechanical sensitivity, thermal sensitivity and motor nerve conduction velocity (MNCV) of
446 sciatic nerve. Immunohistochemical staining of the posterior plantar skin and integrated
447 optical density (IOD) analysis for **(B)** Intraepidermal nerve fibre density (IENFD, marked by
448 PGP9.5). Immunohistochemical staining of **(C)** dorsal root ganglion and **(D)** sciatic nerve and
449 IOD analysis for Neurofilament 200 (NF200), myelin basic protein (MBP) and Brain derived
450 neurotrophic factor (BDNF). **(E)** Immunohistochemical staining of clone and IOD analysis
451 for tight junction proteins ZO-1, Claudin-1 and Claudin-4. **(F)** Plasma levels of LBP, IL-6 and
452 TNF- α . Data are presented as the mean \pm s.e.m. The comparison between the two groups was
453 tested by Student's t-test (two-tailed). * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$. M-DSPN
454 indicates db/db mice received fecal microbiota from patients with DSPN, M-NG indicates
455 db/db mice received fecal microbiota from the subjects with normal glucose level. For A, M-
456 DSPN group, n = 6; M-NG group, n = 6; For B and F, M-DSPN group, n = 4; M-NG group, n
457 = 4; For C, M-DSPN group, n = 3; M-NG group, n = 3; For D and E, M-DSPN group, n = 3;
458 M-NG group, n = 4. For B and C, scale bars indicate 20 μm ; For D and F, scale bars indicate
459 50 μm .

460

461 **Figure 2 | FMT alleviated the severity of peripheral neuropathy, anxiety, depression,**
462 **and improved sleep and life quality in patients with DSPN. (A)** Toronto clinical scoring
463 system (TCSS) score. **(B)** Visual analogue scale (VAS) score. **(C)** Hamilton anxiety scale
464 (HAMA) score; **(D)** Hamilton depression rating scale (HAMD) score. **(E)** Pittsburgh sleep
465 quality index (PSQI) score. **(F)** World health organization's quality of life (WHOQOL)-
466 BREF score. 0D indicates baseline, and 84D indicates 84 days after FMT. In the box plots,
467 the line in the middle of the box is plotted at the median, and the inferior and superior limits
468 of the box correspond to the 25th and 75th percentiles, respectively. The whiskers correspond
469 to the 10th and 90th percentiles, and outliers are denoted. Mann-Whitney U test was used to
470 analyze differences between FMT and Placebo. * $P < 0.05$. Wilcoxon matched-pairs signed
471 rank test was used to analyze each pairwise comparison 0D and 84D within each group. #
472 $P < 0.05$ and ## $P < 0.01$. The bars represent the mean change from the baseline value per group,
473 with the corresponding s.e.m.. Mann-Whitney U test was used to analyze differences in the
474 changes between the FMT and placebo groups (intergroup changes). † $P < 0.05$ and †† $P < 0.01$.
475 FMT group, n = 22; Placebo group, n = 10.

476
477 **Figure 3 | FMT improved gut barrier integrity and systemic inflammatory status in**
478 **patients with DSPN.** Representative immunofluorescence staining of the tight junction
479 proteins **(A)** ZO-1, **(B)** Claudin-1 and **(C)** Claudin-4 in clone. Plasma levels of **(D)** LBP, **(E)**
480 IL-6 and **(F)** TNF- α . Scale bars indicate 20 μ m. 0D indicates baseline, 84D indicates 84 days
481 after FMT. In the box plots, the line in the middle of the box is plotted at the median, and the
482 inferior and superior limits of the box correspond to the 25th and 75th percentiles, respectively.
483 The whiskers correspond to the 10th and 90th percentiles, and outliers are denoted. Student's t-
484 test (two-tailed) (A, B and C) and Mann-Whitney U test (D, E and F) were used to analyze
485 differences between FMT and Placebo. * $P < 0.05$. Paired t-test (two-tailed) (A, B and C) and

486 Wilcoxon matched-pairs signed rank test (D, E and F) was used to analyze each pairwise
487 comparison 0D and 84D within each group. [#] $P < 0.05$ and ^{##} $P < 0.01$. The bars represent the
488 mean change from baseline per group, with the corresponding s.e.m. Student's t-test (two-
489 tailed) (A, B and C) and Mann-Whitney U test (D, E and F) were used to analyze differences
490 in the changes between the FMT and placebo groups (intergroup changes). [†] $P < 0.05$ and ^{††} P
491 < 0.01 . For A and C, FMT group, $n = 6$; placebo group, $n = 5$. For B, FMT group, $n = 4$;
492 placebo group, $n = 5$. For D, E and F, FMT group, $n = 22$; placebo group, $n = 10$.

493

494 **Figure 4 | FMT induced overall structural changes in the gut microbiota in patients with**

495 **DSPN. (A)** Strains from samples were classified by origin (unique to patient at baseline,
496 unique to transplant, present in both patient baseline and transplant, or absent in both patient
497 baseline and transplant). **(B)** Jensen-Shannon distance (JSD) of the gut microbiotas. JSD vs.
498 donor: JSD between a sample at the particular time point and that of the transplant; JSD vs.
499 T0: JSD between a sample at the particular time point and the baseline sample. Data are
500 presented as the mean \pm s.e.m. Wilcoxon matched-pair signed-rank tests were used to analyze
501 each pairwise comparison. $*P < 0.05$ and $**P < 0.01$. **(C)** Richness (number of strains) and
502 diversity (Shannon index) of the gut microbiota. Data are presented as the mean \pm s.e.m.
503 Wilcoxon matched-pair signed-rank tests were used to analyze each pairwise comparison. $*P$
504 < 0.05 and $**P < 0.01$. **(D)** Subject adjusted principal coordinate analysis (aPCoA) of Jaccard
505 distances at the strain level. The lower triangular heat map shows the marginal PerMANOVA
506 test based on Jaccard distance (strata in subject, 999 permutations, $*P < 0.05$ and $**P <$
507 0.01). The box plots show the changes in the gut microbiota from different time points on
508 PC1 or PC2 (the line in the middle of the box is plotted at the median, the inferior and
509 superior limits of the box correspond to the 25th and 75th percentiles, the whiskers
510 correspond to the 10th and 90th percentiles, and outliers are denoted). Wilcoxon matched-pair

511 signed-rank tests were used to analyze each pairwise comparison. $*P < 0.05$, $**P < 0.01$ and
512 $***P < 0.001$. The samples from FMT group in RCT study and samples from Placebo group
513 in the post-RCT study of transplantation with transplants from healthy donors were analyzed
514 together. 0D indicates before transplantation (n = 32), 3D (n = 31), 28D (n = 29), 56D (n =
515 26) and 84D (n = 32) indicate 3 days, 28 days, 56 days and 84 days after transplantation with
516 transplants from healthy donors, respectively.

517

518 **Figure 5 | The gut microbial genomes correlated with TCSS score were organized in two**
519 **competing guilds. (A)** The high-quality metagenome-assembled genomes (HQMAGs) had
520 significantly correlation with TCSS score. The orange bar indicates negative correlation and
521 purple bar indicates positive correlation. **(B)** Co-abundance network of the HQMAGs reflects
522 two competing guilds. The co-abundance correlation between the HQMAGs were calculated
523 using repeated measures correlation. All significant correlations with BH-adjusted $P < 0.05$
524 were included. Edges between nodes represent correlations. Red and blue colors indicate
525 positive and negative correlations, respectively. Node color indicates Guild 1 (orange) and
526 Guild 2 (purple), respectively. **(C)** The abundance of Guild 1 and Guild 2 in transplants and
527 fecal samples from patients. The samples from FMT group in RCT study and samples from
528 Placebo group in the post-RCT study of transplantation with transplants from healthy donors
529 were analyzed together. 0D indicates before transplantation (n = 32), 3D (n = 31), 28D (n =
530 29), 56D (n = 26) and 84D (n = 32) indicate 3 days, 28 days, 56 days, and 84 days after
531 transplantation with transplants from healthy donors, respectively. Data are presented as the
532 mean \pm s.e.m. Wilcoxon matched-pair signed-rank tests (two-sided) were used to compare
533 differences of abundance between Guild 1 and 2 at the same timepoint, $***P < 0.001$. Mann-
534 Whitney tests were used to compare transplants and recipients, $^{\#} P < 0.05$ and $^{\#\#} P < 0.01$. **(D)**

535 Functional genes in the HQMAGs significantly correlated with TCSS score. The encode key
536 enzymes in the propionate, butyrate and indole production, lipid A biosynthesis pathways and
537 antibiotic resistant genes are shown in the right part of the cycle. The HQMAGs that were
538 significantly corelated with TCSS score and whose genomes contain these genes are shown in
539 the left part of the cycle. The linkage between strains and genes indicates that the genome of
540 the strain contained the gene. The orange line indicates that the HQMAGs negatively
541 corelated with TCSS score, whereas the purple line indicates that the HQMAGs positively
542 corelated with TCSS score pst: propionyl-CoA:succinate-CoA transferase; pct: propionate
543 CoA transferase; but: butyryl-coenzyme A (butyryl-CoA):acetate CoA transferase; tnaA:
544 tryptophanase; arnT: 4-amino-4-deoxy-L-arabinose transferase; lpxA: UDP-N-
545 acetylglucosamine acyltransferase; lpxB: lipid A disaccharide synthase; lpxCf (lpxC-fabZ):
546 bifunctional enzyme LpxC/FabZ; lpxD: UDP-3-O-(3-hydroxymyristoyl)glucosamine N-
547 acyltransferase; lpxH: UDP-2,3-diacylglucosamine hydrolase; lpxK: tetraacyldisaccharide 4'-
548 kinase; lpxL: lipid A biosynthesis lauroyltransferase; ARGs: antibiotic resistant genes.

549

550 **Figure 6 | Matched enterotype between FMT transplants and recipients linked to better**

551 **improvement of DSPN. (A)** Classification of two enterotypes among all samples based on
552 Jaccard distance and complete linkage. The samples included all the transplants, FMT group
553 in RCT study and Placebo group in the post-RCT study of transplantation with fecal
554 microbiota of healthy donors. *Calinski-Harabasz* (CH) index was used to assess the optimal
555 number of clusters. **(B)** The enterotype of baseline gut microbiota of recipients paired with
556 their transplants. **(C)** The abundance of Guild 1 and Guild 2 in matched and unmatched
557 groups. The samples from FMT group in RCT study and samples from Placebo group in the
558 following trial of transplantation with transplants from healthy donors were analyzed together.
559 Matched group indicates the baseline gut microbiota of recipients and their transplants belong

560 to the same enterotype (n = 24). unmatched group indicates the baseline gut microbiota of
561 recipients and their transplants belong to the different enterotypes (n = 8). 0D indicates before
562 transplantation, 3D, 28D, 56D and 84D indicate 3 days, 28 days, 56 days and 84 days after
563 transplantation with transplants from healthy donors, respectively. Data are presented as the
564 mean \pm s.e.m. Mann-Whitney U test was used to analyze differences of abundance of Guild 1
565 or 2 between matched and unmatched groups, * $P < 0.05$. Friedman test followed by Nemenyi
566 post-hoc test was used to compare the different timepoints within the same group, and values
567 of each group with same letters are not significantly different ($P > 0.05$). (D) Changes of
568 TCSS score in matched and unmatched groups. In the box plots, the line in the middle of the
569 box is plotted at the median, and the inferior and superior limits of the box correspond to the
570 25th and 75th percentiles, respectively. The whiskers correspond to the 10th and 90th
571 percentiles, and outliers are denoted. Mann-Whitney U test was used to analyze differences
572 between matched and unmatched groups. * $P < 0.05$. Wilcoxon matched-pairs signed rank
573 test was used to analyze each pairwise comparison 0D and 84D within each group. # $P < 0.05$
574 and ## $P < 0.01$. The bars represent the mean change from the baseline value per group, with
575 the corresponding s.e.m. Mann-Whitney U test was used to analyze differences in the changes
576 between the matched and unmatched groups (intergroup changes).

577

578 **STAR ★ METHODS**

579 Detailed methods are provided in the online version of this paper and include the following:

580 **KEY RESOURCES TABLE**

581 **CONTACT FOR REAGENT AND RESOURCE SHARING**

582 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

583 ● Clinical Study

584 ● Animal study with db/db Mice

585 **METHOD DETAILS**

586 ● Questionnaire

587 ● Neurophysiological Examination

588 ● Immunofluorescence and Immunohistochemistry

589 ● Serum ELISA

590 ● Gut Microbiome Analysis

591 **QUANTIFICATION AND STATISTICAL ANALYSIS**

592 ● Statistical Analysis of clinical data

593 ● Statistical analysis of gut microbiota data

594 **DATA AND SOFTWARE AVAILABILITY**

595 **STAR ★ Methods**

596 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Human ZO-1 Rabbit Polyclonal antibody	Proteintech	21773-1-AP
Human Anti-Claudin-1 antibody	Abcam	Ab211737
Human Anti-Claudin 4 antibody	Abcam	Ab53156

Goat anti-rabbit cyanine 3 (Cy3) (red)	Boster Biological Technology	BA1032
Mouse Anti-ZO-1 antibody	Servicebio	GB111981
Mouse Anti-Claudin-1 antibody	Servicebio	GB11032
Mouse Anti-Claudin 4 antibody	Proteintech	16195-1-AP
Mouse Anti-NF 200 antibody	Proteintech	18934-1-AP
Mouse Anti-MBP antibody	Abcam	Ab218011
Mouse Anti-BDNF antibody	Abcam	Ab108319
Goat Anti-Rabbit IgG	Servicebio	GB23303
Critical Commercial Assays		
Human TNF- α Immunoassay ELISA kit	R&D Systems Minneapolis	HSTA00E
Human IL-6 ELISA Kit	Shanghai Jianglai Industrial Limited by Share Ltd.	JL14113
Human LBP ELISA kit	Hycult®Biotec	HK315
Mouse LBP ELISA Kit	Elabscience	E-EL-M2686c
Mouse IL-6 ELISA Kit	Elabscience	E-EL-M0044c
Mouse TNF- α ELISA Kit	Elabscience	E-EL-M3063
PowerFecal® DNA Kit	QIAamp	12830-50
Deposited Data		
NCBI	https://www.ncbi.nlm.nih.gov/sra	SRP379656, SRP278004, SRP272175
ENA	https://www.ebi.ac.uk/ena/browser/home	PRJEB53551
Software and Algorithms		
R project (version 3.5.3)	CRAN	https://cran.r-project.org/
blockrand (version1.5) in R project		https://cran.r-project.org/mirrors.html
MASS (version 7.3-51.4) in R project		https://cran.r-project.org/mirrors.html
ade4 (version 1.7-15) in R project		https://cran.r-project.org/mirrors.html

QIIME 2 version 2019.10	https://qiime2.org	
CoverM v0.6.1	https://github.com/wwood/CoverM	
Resistant gene identifier 5.2.1	https://card.mcmaster.ca/analyze/rgi	

597 CONTACT FOR REAGENT AND RESOURCE SHARING

598 Further information and requests for resources and reagents should be directed to and will be
599 fulfilled by the Lead Contact, Huijuan Yuan (hjyuan@zzu.edu.cn)

600 EXPERIMENTAL MODEL AND SUBJECT DETAILS

601 Clinical Study

602 The studies were approved by the Medical Ethics Committee of Henan Provincial People's
603 Hospital and written informed consent was obtained from all participants.

604 Comparison of gut microbiota among subjects with normal glucose level and DM 605 patients with or without DSPN

606 Firstly, we recruited 27 patients with DSPN. Patients were recruited if they were (1) type 1 or
607 type 2 diabetes with DSPN. The diagnosis of DSPN was according to the criteria
608 recommended by 2017 American Diabetes Association(Pop-Busui et al., 2017). According to
609 the criteria, the patients had (i) at least one abnormal symptoms (including local or distal
610 numbness, pain, formication, and tingling) and signs (including pinprick sensation,
611 temperature sensation, vibration perception, proprioception, 10-g monofilament, and ankle
612 reflexes), with TCSS score > 5 or VAS score \geq 4; (ii) excluded other disease caused
613 peripheral neuropathy; (2) aged 18-70 years old; (3) with glycated haemoglobin (HbA1c)
614 <11%; (4) responded poorly to conventional treatments for at least 3 months (84days).

615 Besides, the conventional treatments include lifestyle modification, glucose control, and drug
616 intervention; the patients responded poorly to conventional treatments means their TCSS
617 scores decreased by < 3 and/or VAS scores decreased by $< 25\%$ as compared to that before
618 treatment.

619 Patients were excluded if they (1) had a continuous antibiotic use history for > 3 days
620 within 3 months prior to enrolment; (2) had any clinically significant or unstable mental or
621 psychiatric illnesses or epilepsy; (3) had other causes of neuropathy, such as osteoarthritis,
622 cervical lumbar diseases, connective tissue disease, peripheral vascular disease, tumor
623 peripheral neuropathy, herpes zoster infection, abnormal thyroid function, or severe
624 malnutrition; (4) had undergone gastrectomy, fundoplication, colostomy or other digestive
625 system surgery; (5) had persistent vomiting or a suspected gastrointestinal obstruction; (6) had
626 taken drugs that can cause peripheral neuropathy, such as isoniazid or furazolidone; (7) had
627 severe cardiovascular and cerebrovascular diseases or liver, kidney and haematopoietic
628 system diseases; (8) had alcoholism (drinking more than 5 times in one week, more than 100
629 g of spirits, 250 g of rice wine or 5 bottles of beer); (9) were pregnant; (10) had a physical
630 disability or self-care disability or were unable to recall clearly and answer questions due to
631 any other reasons; or (11) lacked the time to take part in this project. Written informed
632 consent was obtained from all participants. The feces were collected and stored at -80°C .

633 From our previous clinical trial with the DM patients published by Xinru Deng et al
634 (Deng et al., 2022), we selected 30 age- and sex- matched patients without DSPN (had no
635 DSPN symptoms and TCSS score ≤ 5 , $n=30$) and used their baseline data (before drug
636 treatment). The data of the subjects with normal glucose level ($n=29$) was obtained from our
637 previous cohort study published article by Yuanyuan Fang et al (Fang et al., 2021).

638 **Randomized controlled trial**

639 This randomized, double-blind, placebo-controlled pilot clinical trial was registered in the
640 Chinese Clinical Trial Registry (ChiCTR1800017257), and performed from August 2018 to
641 February 2022. Written informed consent was obtained from all participants.

642 *Sample Size Estimation*

643 Because no clinical trials of FMT treating DSPN performed previously, the proof of concept
644 study enrolled 39 subjects. No sample size calculation was performed.

645 According to this observed magnitude of changes (3.09 in FMT v.s. 0.6 in Placebo) and
646 standard deviation (2.4 in FMT and Placebo) of TCSS scores from our RCT study, the power
647 calculation estimated that 36 participants (FMT: Placebo=2:1) would provide $\alpha=0.05$, 1-
648 $\beta=0.8$, and there would be approximately 40 subjects participate coupled with a dropout rate
649 of 10%. Then the sample size of our RCT study was similar with this calculated value.

650 *Study Subjects*

651 We recruited DSPN patients with the same inclusion and exclusion criteria as the above
652 description. And the participant flow was shown in Figure S3.

653 *Clinical trial of FMT*

654 During the 14-day run-in period, all antidiabetic medications except insulin were withdrawn,
655 all conventional treatments for DSPN was stopped and other non-diabetic drugs which long
656 term use before FMT remained unchanged to avoid potential confounding effects on the gut
657 microbiota. At the same time, all patients were given dietary guidance according to the
658 Diabetic Diet Guidelines in Chinese (2017). At baseline, all participants' characteristics were
659 assessed comprehensively, peripheral blood was collected for chemical and biological
660 analyzes, and stool samples were collected for gut microbiota analysis. Upon successful

661 completion of the 14-day run-in, participants were randomly assigned to the intervention or
662 control group in a 2:1 ratio and followed up for 84 days.

663 Randomization codes were determined by a computer-generated random sequence
664 (random sequence generation by blockrand (version1.5) package was performed using R
665 project). In order to double-blind, the randomization and the placebo was conducted by the
666 operator of nonprofit China fmtBank who did not participate in the enrolment and
667 transplantation process. All the doctors and operators were blinded, and unblind was given by
668 the nonprofit China fmtBank after the patients completed the last visit (84 days).

669 The primary indicator of the study was the change of TCSS score at 84D compared with
670 baseline and the secondary indicators included the change of VAS score, HAMA score,
671 HAMD score, PSQI and WHOQOL-BREF score, NCV and CPT at 84D compared with
672 baseline. All adverse events were recorded and described according to the Common
673 Terminology Criteria for Adverse Events (CTCAE). The mechanism indexes were the
674 structure and function of gut microbiota, inflammatory cytokine and gut barrier integrity.

675 *Donor selection and transplants preparation*

676 Donors were selected and screened by the nonprofit China fmtBank. The criteria for FMT
677 donor screening included eight aspects: age, physiology, pathology, psychology, veracity,
678 time, living environment and recipients. The ages of the donors ranged from 18-24 years, and
679 all of them were evaluated for physiological status, such as for body growth, body mass
680 index, sleep quality, daily habits, diet, physical exercise and regular bowel habits. The
681 detailed protocol was reported in our previous papers (Ding et al., 2019; Zhang et al., 2020).

682 The methodology of FMT used in the present study was recently designated washed
683 microbiota transplantation (Zhang et al., 2020), which was performed using automated

684 instruments (GenFMter, FMT Medical, Nanjing, China) in a biosafety level 3 laboratory at
685 Nanjing Medical University. Information regarding the donors and laboratory processes was
686 recorded by the China Microbiota Transplantation System (CMTS). We used the one-hour
687 protocol, which requires all steps from defecation to storage of the microbiota suspension in a
688 -80°C freezer to be conducted within one hour. The enriched microbiota was collected
689 according to the washed preparation protocol reported by recent report (Zhang et al., 2020)
690 and the panel consensus report (2020). The placebo, which was identical in appearance, form,
691 color and size to the frozen microbiota, was composed of saline with food grade coloring
692 pumpkin powder and purple potato powder (total 13.2g for the total administration per day).

693 ***FMT delivery and follow-up***

694 The methods used for delivering the washed microbiota were described in our previous report
695 (Dai et al., 2019). Briefly, patients were prepared according to the method used for routine
696 gastroscopy and colonoscopy. Patients underwent mid-gut transendoscopic enteral tubing
697 (TET) for insertion of a 2.7 mm outer-diameter tube under anaesthesia (Long et al., 2018). All
698 patients underwent colonoscopy to exclude complicated intestinal diseases, and six mucosal
699 biopsies were obtained at the junction of the descending and sigmoid colons in both FMT
700 (n=6) and placebo (n=5) group. Tissues were stored in liquid nitrogen for further
701 immunofluorescence testing. The frozen fecal microbiota or placebo from China fmtBank was
702 thawed to 37°C in a water bath. Total 150 mL rewarming suspension with 5×10^{13} of bacteria
703 as the total dose per day was delivered into intestine via mid-gut tube. Total two doses were
704 delivered within two days. The patients were blinded to the infusion provided by operators.
705 Patients maintained a seated position for 30 min and fasting state for 2 h after transplant. The
706 microbiota from the same batch was infused through the mid-gut TET tube on the second day.

707 All patients were evaluated at scheduled follow-up visits at 3 days (3D), 28 days (28D),
708 56 days (56D) and 84 days (84D) after FMT. The antibiotics, probiotics, and yogurt were
709 unable to be taken throughout the follow-up. At each visit, patients underwent examination of
710 the TCSS, VAS, HAMA, HAMD, PSQI and WHOQOL standards, and dietary guidance was
711 given at the same time, all of them were conducted by one experienced and constant
712 investigator. Peripheral blood was collected and serum samples were stored at -80°C. The
713 stool samples were collected and stored at -80°C. Moreover, the levels of NCV and CPT were
714 also assessed at baseline (0D) and at the end point (84D). Most notably, for the last visit
715 (84D), all the above operating procedures were accomplished before unblinding. All adverse
716 events described according to the Common Terminology CTCAE were submitted to the
717 CMTS for long-term monitoring. The grade refers to the adverse event severity. The CTCAE
718 displays grades 1–5 with clinical descriptions of adverse event severity based on the
719 guidelines (Table S4).

720 **Post-RCT study**

721 After finishing the RCT study, all patients in the placebo group of the above RCT received
722 transplants made from fecal microbiota of the healthy donors, following with the same
723 protocol of the RCT study for treatment, follow-up, test of clinical parameters and samples
724 collection.

725 **Animal study with db/db Mice**

726 **Preparation of transplants from DSPN patients and NG subjects**

727 In the anaerobic operating chamber (80% N₂:10% CO₂:10% H₂, Don Whitley Scientific,
728 UK), an equal amount of frozen feces from DSPN patients (n=5) or NG subjects (n=5) were
729 melted and mixed at 37°C. Each mixed fecal material (1 g) was diluted in 50 mL of a sterile

730 Ringer working buffer (9 g/L of sodium chloride, 0.4 g/L of potassium chloride, 0.25 g/L of
731 calcium chloride dehydrate and 0.05% (w/v) L-cysteine hydrochloride). The diluted fecal
732 materials were suspended by vortex for 5 min and then settled by gravity for 5 min. The
733 clarified supernatant was transferred to a clean tube, and an equal amount of 20%(W/V) skim
734 milk was added. The transplant was prepared fresh on the day of the transplantation
735 experiment, and the rest was stored at -80°C until the inoculation.

736 **Animal study**

737 All animal experimental procedures were approved by the Committee of Animal
738 Experimental Center of Zhengzhou University (ZZU-LAC20211015[10]), and were
739 conducted according to the committee's guidelines. Teen-week-old SPF male BKS-DB
740 (Lepr)(db/db) mice were purchased from Jiangsu Jijiyukang Biotechnology Co., LTD.
741 (Certificate No. SCXK(Su)2018-0008) and kept under SPF environment at the Zhengzhou
742 University Experimental Animal Center. The mice were fed with a sterilized normal chow
743 diet (3.9kcal/g; HUANYU BIO, GB 14924.3-2010) and housed in a room maintained at 22 ±
744 2 °C with humidity of 50%±10%, with a 12 h light/dark phase cycle (lights on at 07:00 am).

745 After one-week of acclimation, all the db/db mice were treated with vancomycin (0.5
746 g/L), neomycin sulfate (1g/L), ampicillin (1g/L) and metronidazole (1g/L) in drinking water.
747 After 2 weeks with the antibiotic cocktail treatment, the mice were then randomly assigned to
748 2 groups: (i) M-DSPN group (n = 6), the db/db mice inoculated with transplant from DSPN
749 patients; (ii) M-NG group (n = 6), the db/db mice inoculated with transplant from NG
750 subjects. The oral gavage was performed once a day for the first 3 days, and strengthened
751 once every 3 days. After 3 weeks, the feces were collected and mechanical sensitivity, thermal
752 sensitivity and motor nerve conduction velocity were used to measure neuropathic indicators.

753 Then the mice were scarified, and the blood samples and tissues of clone, dorsal root ganglion
754 and sciatic nerve were collected. All the samples were stored at -80°C.

755 **METHOD DETAILS**

756 **Questionnaire**

757 **Toronto Clinical Scoring System (TCSS)**

758 The severity of DSPN was assessed with TCSS (Arumugam et al., 2016), which including the
759 scores of symptoms, reflexes and sensory tests. The symptom scores contain pain, numbness,
760 tingling and weakness of the lower limb; ataxia and symptoms of upper limb. The deep
761 tendon reflexes contain knee and ankle reflexes. The sensory tests contain pinprick sensation,
762 temperature sensation, light touch, vibration and position, which were performed on the first
763 toe. The TCSS was investigated by one experienced and constant investigator.

764 Symptom scores: score of 0 represents absent, score of 1 represents present. Reflex
765 scores: score of 2 represents absent, score of 1 represents reduced, score of 0 represents
766 normal. Sensory test scores: score of 1 represents abnormal, score of 0 represents normal. The
767 higher the overall score, the more severe the symptoms.

768 **Visual Analogue Scale (VAS)**

769 The severity of neuropathic pain of the patients were evaluated by VAS (Petersen et al.,
770 2021). 10 cm of Horizontal line was drawn on the paper, one end of the horizontal line is 0,
771 indicating no pain; the other end is 10, indicating severe pain; the middle part shows different
772 levels of pain. The patients were asked to mark the level of any form of pain on the line
773 according to their feelings. A score of 1–3 indicated mild pain and 4–10 indicated
774 moderate/severe pain.

775 **Hamilton Anxiety Scale (HAMA)**

776 Anxiety was evaluated by means of the Hamilton Anxiety Scale (HAMA (Zhao et al., 2021)).
777 HAMA includes 14 items; each item is scored from 0 to 4, with a higher score reflecting more
778 severe anxiety.

779 **Hamilton Depression Rating Scale (HAMD)**

780 Depression was assessed by means of the Hamilton Depression Scale (HAMD (Zhao et al.,
781 2021)). It consists of 17 items; each item is scored from 0 (not present) to 7 (severe), with a
782 higher total score indicating more severe depression.

783 **Pittsburgh Sleep Quality Index (PSQI)**

784 The sleep quality was evaluated by PSQI (Buysse et al., 1989), which mainly consists of 19
785 self-rated questions, which assess a wide variety of factors relating to sleep quality, including
786 estimates of sleep duration and latency and of the frequency and severity of specific sleep-
787 related problems. These 19 items are grouped into seven component scores, each weighted
788 equally on a 0-3 scale. The seven component scores are then summed to yield a global PSQI
789 score, which has a range of 0-21; higher scores indicate worse sleep quality.

790 **Brief table of the World Health Organization's Quality of Life (WHOQOL-BREF)**

791 The quality of life was assessed by WHOQOL-Bref (Chiu et al., 2006; Saxena et al., 2001),
792 which containing 26 items and are represented by the most suitable one item for each of 24
793 WHOQOL-100 facets. The 24 facets or items are further categorized into four domains:
794 physical capacity (7 items), psychological well-being (6 items), social relationships (3 items),
795 and environment (8 items). Each item uses a scale from 1 to 5, with a higher score indicating
796 a higher quality of life. Domain scores are calculated by multiplying the mean of all facet

797 scores included in each domain by a factor of 4, and potential scores for each domain vary
798 from 4 to 20 (e.g., score of social relationships = $((Q20 + Q21 + Q22)/3) * 4$).

799 **Neurophysiological Examination**

800 **CPT**

801 The Neurometer^RCPT detector (Neurotron Inc., Baltimore, USA) was used to test CPT, which
802 was operated by one experienced and constant investigator following the standard protocol of
803 the equipment. The patient took a seat position, fully exposed the inspection site and the room
804 temperature kept at 24 ± 1 degrees. There were four test sites, the distal phalanx of index finger
805 on the both dorsal hands and the distal phalanx of hallux on the both dorsal feet. The test
806 points were stimulated with 2000Hz, 250Hz and 5Hz sine wave current. According to the
807 manufacturer, each result below or above the reference range was defined as hyperesthesia or
808 hypoesthesia, respectively.

809 **Nerve conduction velocity**

810 For clinical studies, electromyography (MEB-9400C, Nihon Kohden Corporation, Tokyo,
811 Japan) was used to assess the MNCV and SNCV, which was operated by one experienced and
812 constant investigator following the standard protocol of the equipment. The patient took a
813 supine position, fully exposing the test site and surface electrodes were used to stimulate the
814 nerve. The patient's limb temperature was maintained at 32 degrees and the room temperature
815 was kept at 28-30 degrees.

816 For mice study, nerve conduction velocity (NCV) was measured as described previously
817 (Goss et al., 2002) with slight modifications. Mice were anesthetized with 10ml/kg chloral
818 hydrate and electrodes were placed at the acrotarsium and sciatic notch. Nicolet EDX

819 electromyography instrument was used to record simultaneous electromyography during
820 electrical stimulation, and the motor nerve conduction velocity (MNCV) was calculated.

821 **Mechanical and Thermal Sensitivities**

822 For mice study, mechanical allodynia was assessed using calibrated Von Frey filaments
823 (Stoelting) and thermal hyperalgesia was assessed by a thermal stimulation meter (YLS-6B)
824 according to published methods (Fan et al., 2020).

825 **Immunofluorescence and Immunohistochemistry**

826 **Immunofluorescence analysis of the tight junction proteins in colon of patients**

827 Frozen sections (4 μm thickness) were prepared from colon tissue from patients with a
828 freezing microtome (Cryotome E, Thermo, MA, USA). Slides were blocked with diluted goat
829 serum and then incubated with primary antibodies against ZO-1 (1:100), Claudin-1 (1:100),
830 and Claudin-4 (1:100) at 4°C overnight. After being washed with PBST, the sections were
831 incubated with goat anti-rabbit cyanine 3 (Cy3) (red) secondary antibodies (Boster Biological
832 Technology, CA, USA). Nuclei were visualized with 4-6-diamidino-2-phenylindole-2 HCl
833 (DAPI, Beyotime, Jiangsu, China). The stained slides were then scanned by scanning
834 confocal microscopy (BX53, Olympus, Tokyo, Japan).

835 For each immunofluorescence marker, we assessed a single 5-mm section. Three regions
836 of interest (ROIs) were manually selected from each 5-mm section per marker per sample.
837 Each ROI measured $0.5 \times 0.5 \text{ mm}^2$, and the density of each marker plotted for each time point
838 represents the mean of the four ROIs per mm^2 . The immune infiltrate density was quantified
839 digitally by using Image-Pro Plus 6.2 (Media Cybernetics Inc., Rockville, MD, USA).

840 **Immunohistochemistry analysis in mice study**

841 ***Intraepidermal nerve fiber density measurement***

842 The plantar skin of the mice was drilled horizontally with a skin biopsy instrument with a
843 diameter of 2mm. The plantar skin including epidermis and dermis was cut out by ophthalmic
844 scissors and directly fixed with 4% paraformaldehyde for subsequent immunohistochemistry.
845 Intraepidermal nerve fibre density (IENFD) was measured using PGP9.5 antibody staining in
846 a blinded fashion. Sections were restrained with eosin (Sigma-Aldrich Eosin Y solution
847 HT110316) to depict the fiber crossing at the dermoepidermal junction. IENFD was
848 calculated (as fibres/mm) by the number of complete baseline crossings of nerve fibres at the
849 dermo-epidermal junction (Chandrasekaran et al., 2019).

850 ***Dorsal root ganglion and sciatic nerve***

851 The paraffin-embedded sections of dorsal root ganglion, sciatic nerve tissue and colon tissue
852 samples were deparaffinized by xylene and dehydrated by different concentration of alcohol
853 solutions and then were treated with citrate or EDTA buffer for antigen retrieval. 3 % H₂O₂
854 was used to block endogenous peroxidase for 15 min, followed by diluted goat serum to
855 reduce nonspecific staining for 30 min. For dorsal root ganglion and sciatic nerve tissue, the
856 sections were incubated with anti-NF 200 (1:300), anti-MBP (1:1000) and anti-BDNF (1:500)
857 primary antibodies at 4 °C overnight.

858 ***Tight junction proteins in colon***

859 The colon tissue samples the sections were incubated with anti-claudin-1 (1:600), anti-
860 claudin-4 (1:200) and anti-ZO-1 (1:300) primary antibodies at 4 °C overnight. After
861 incubation and subsequent washing, the secondary antibodies corresponding to the primary
862 antibody were added to the samples and incubated at room temperature for 50 min. After
863 washing three times with PBS, the slices were stained with diaminobenzidine (DAB). Images

864 were obtained using a microscope and positive DAB-stained areas were calculated by the
865 ImageJ software.

866 **Serum ELISA**

867 For clinical studies, commercially available ELISA kits were used to determine serum levels
868 of LBP (HK315, Hycult@Biotech, UDEN, Netherlands), TNF- α (HSTA00E, QuantikineHS,
869 R&D Systems Minneapolis, MN, USA) and IL-6 (JL14113, Shanghai Jianglai Industrial
870 Limited by Share Ltd., shanghai, China). The minimum detectable concentrations for LBP,
871 TNF- α and IL-6 were 4.4 ng/mL, 0.011 pg/mL and 3.12 pg/mL, respectively.

872 For mice study, commercially available ELISA kits were used to determine serum levels
873 of LBP (E-EL-M2686c, Elabscience, Wuhan, China), TNF- α (E-EL-M3063, Elabscience,
874 Wuhan, China) and IL-6 (E-EL-M0044c, Elabscience, Wuhan, China). The minimum
875 detectable concentrations for LBP, TNF- α and IL-6 were 3.13 ng/mL, 7.81pg/mL and 31.25
876 pg/mL, respectively.

877 **Gut Microbiome Analysis**

878 **DNA extraction**

879 Genomic DNA was extracted from human and mice feces using the QIAamp PowerFecal Pro
880 DNA Kit (QIAGEN, USA, 51804).

881 **16S rRNA gene V3-V4 region sequencing**

882 PCR targeting the V3-V4 region of the 16S rRNA gene with primers Forward [5'-
883 CCTACGGGNGGCWGCAG -3'] and Reverse [5'-GACTACHVGGGTATCTAATCC -3']

884 (Klindworth et al., 2013). The subsequent amplicon sequencing was performed on a MiSeq
885 platform to generate paired-end reads of 300 bp (Illumina, CA, USA).

886 The reads were analyzed using QIIME2 version 2019.7 (Bolyen et al., 2019). Then the
887 adapters of the sequences were removed using the "cutadapt" plugin of QIIME2. DADA2 was
888 used to obtain the abundance and representative sequences of amplicon sequence variants
889 (ASVs) (Callahan et al., 2016). Afterwards, the ASVs of three batches were merged using the
890 QIIME2. Representative sequences for ASVs were built into a phylogenetic tree using core-
891 metrics-phylogenetic pipeline in QIIME2 and were assigned into taxonomy using Silva
892 database (release 132) (Quast et al., 2013). All the samples were randomly subsampled to
893 equal depths of 23154 reads prior to the following analysis.

894 α -diversity analysis and principal coordinate analysis (PCoA) were conducted using
895 QIIME2 diversity plugins. Permutational multivariate analysis of variance test
896 (PERMANOVA, 999 tests) was performed using R package vegan.

897 **Shot-gun Metagenomic Sequencing**

898 DNA was sequenced using an Illumina HiSeq 3000 at GENEWIZ Co. (Beijing, China).
899 Cluster generation, template hybridization, isothermal amplification, linearization, and
900 blocking of denaturation and hybridization of the sequencing primers were performed
901 according to the workflow specified by the service provider (Liu et al., 2016). Libraries were
902 constructed with an insert size of approximately 500 bp, followed by high-throughput
903 sequencing to obtain 150 bp paired-end reads in the forward and reverse directions.

904 Trimmomatic (Bolger et al., 2014) was employed to 1) trim adapters 2) remove low-
905 quality bases and 3) remove short reads less than 60 bp in length. Reads that could be aligned
906 to the human genome (*Homo sapiens*, UCSC hg19) were removed (aligned with Bowtie2

907 (Langmead and Salzberg, 2012)). The numbers of high quality reads obtained for each sample
908 are shown in Table S6.

909 *De novo* assembly was performed for each sample with IDBA_UD (Peng et al., 2012).
910 The assembled contigs were further binned by using MetaBAT2 (Kang et al., 2019) with
911 default parameters. CheckM (Parks et al., 2015) was used to assess the quality of the bins.
912 Bins with completeness > 95%, contamination < 5% and strain heterogeneity < 0.05 were
913 retained as high-quality draft genomes (Table S7). To improve the analysis, we also
914 downloaded genomes from the HGG constructed by Samuel *et al* (Forster et al., 2019). The
915 assembled high-quality draft genomes and the HGG genomes were dereplicated by using
916 dRep (Olm et al., 2017) to obtain nonredundant genomes for further analysis (if the dRep
917 cluster contained the draft genomes assembled from our dataset, we used the best genomes
918 within the assembled genomes as the representative genomes of the clusters). The abundance
919 of the genomes was calculated using CoverM v0.6.1 (<https://github.com/wwood/CoverM>)
920 with parameters: --min-read-aligned-percent 90 --min-read-percent-identity 99. Taxonomic
921 assignment of the genomes was performed by using GTDB-Tk (Chaumeil et al., 2019) (Table
922 S8).

923 Prokka (Seemann, 2014) was used to annotate the nonredundant genomes.
924 KofamKOALA (Aramaki et al., 2020) was used to assign KEGG orthologue IDs to the
925 predicted protein sequences in each genome by HMMSEARCH against KOfam. Lipid A
926 biosynthesis associated genes were identified based on the KEGG ontology (KO) ID. The
927 overall structural changes in gut microbial function after FMT were represented by PCoA of
928 Bray-Curtis distances using KEGG Ontology (KO), which revealed the significant changes in
929 gut microbial function after FMT product introduction, corresponding to the strain-level
930 analysis results. The protein sequences for formate-tetrahydrofolate ligase, propionyl-CoA:

931 succinate-CoA transferase and propionate CoA transferase were obtained from the NCBI
932 database with a text search. The protein sequences for 4Hbt, AtoA, AtoD, Buk and But were
933 obtained from the IMG database as described previously (Vital et al., 2014). The predicted
934 protein sequences in each genome were aligned to these sequences using BLASTP (best hit
935 with E-value $< 1e^{-5}$, identity $> 80\%$ and coverage $> 70\%$). Antibiotic resistance genes were
936 identified by Resistance Gene Identifier based CARD database (Alcock et al., 2020).

937 **QUANTIFICATION AND STATISTICAL ANALYSIS**

938 **Statistical Analysis of Clinical Data**

939 Statistical analyzes were performed using R project (version 3.5.3). Values are expressed as
940 the mean \pm s.e.m., median with interquartile range (IQR), or number. For clinical study, One-
941 way ANOVA or Kolmogorov-Smirnov test was used to detect the differences in clinical
942 parameters among the DSPN, DM and NG groups. Mann-Whitney U was used to detect the
943 differences between DM and NG groups. During the RCT study, Mann-Whitney U Test,
944 Student's t-test (two-tailed) or Chi-squared test was used to detect the differences between
945 FMT and placebo group; Paired t-test (two-tailed) or Wilcoxon matched-pair signed-rank test
946 was used to analyze each pairwise comparison within each group. During the post-RCT study,
947 One-Way RM ANOVA test was used to analyze differences between the three time point. For
948 animal study, Student's t-test (two-tailed) was used to compare the differences between the
949 two groups. All the above statistical calculation methods were carried out by MASS (version
950 7.3-51.4) package or ade4 (version 1.7-15) package.

951 **Statistical Analysis of Gut Microbiota Data**

952 Subject adjusted PCoA plot of the genomes based on Jaccard distance were performed with
953 aPCoA package (Shi et al., 2020). Wilcoxon matched-pair signed-rank tests were used to

954 analyze each pairwise comparison and performed using package MASS (version 7.3-51.4) in
955 R project. MaAslin2(Mallick et al., 2021) was used to find genomes associated with TCSS
956 score using linear mixed effect model with subject as random effect. The default significance
957 cutoff adjusted P value < 0.25 was used in our study. Repeat measure correlation was used to
958 calculated the co-abundance correlations between TCSS correlated genomes (Bland and
959 Altman, 1995).

960 DATA AND SOFTWARE AVAILABILITY

961 The data that support the findings of this study are available from the corresponding author
962 upon request. Metagenomic sequence data have been submitted in DDBJ
963 (<http://www.ddbj.nig.ac.jp>) with accessions number DRA009982. Amplicon sequence data
964 have been submitted in NCBI SRA (<https://www.ncbi.nlm.nih.gov/sra>) with accessions
965 number SRP379656, SRP278004 and SRP272175.

966 REFERENCES

- 967 (2020). Nanjing consensus on methodology of washed microbiota transplantation. *Chinese medical journal* *133*,
968 2330-2332.
- 969 Alcock, B.P., Raphenya, A.R., Lau, T.T.Y., Tsang, K.K., Bouchard, M., Edalatmand, A., Huynh, W., Nguyen,
970 A.V., Cheng, A.A., Liu, S., *et al.* (2020). CARD 2020: antibiotic resistance surveillance with the comprehensive
971 antibiotic resistance database. *Nucleic acids research* *48*, D517-D525.
- 972 Aramaki, T., Blanc-Mathieu, R., Endo, H., Ohkubo, K., Kanehisa, M., Goto, S., and Ogata, H. (2020).
973 KofamKOALA: KEGG Ortholog assignment based on profile HMM and adaptive score threshold.
974 *Bioinformatics* *36*, 2251-2252.
- 975 Arumugam, T., Razali, S.N., Vethakkan, S.R., Rozalli, F.I., and Shahrizaila, N. (2016). Relationship between
976 ultrasonographic nerve morphology and severity of diabetic sensorimotor polyneuropathy. *Eur J Neurol* *23*, 354-
977 360.
- 978 Bland, J.M., and Altman, D.G. (1995). Calculating correlation coefficients with repeated observations: Part 1--
979 Correlation within subjects. *BMJ* *310*, 446.
- 980 Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data.
981 *Bioinformatics* *30*, 2114-2120.
- 982 Bolyen, E., Rideout, J.R., Dillon, M.R., Bokulich, N.A., Abnet, C.C., Al-Ghalith, G.A., Alexander, H., Alm,
983 E.J., Arumugam, M., Asnicar, F., *et al.* (2019). Reproducible, interactive, scalable and extensible microbiome
984 data science using QIIME 2. *Nat Biotechnol* *37*, 852-857.
- 985 Bonhof, G.J., Herder, C., Strom, A., Papanas, N., Roden, M., and Ziegler, D. (2019). Emerging Biomarkers,
986 Tools, and Treatments for Diabetic Polyneuropathy. *Endocr Rev* *40*, 153-192.
- 987 Bonomo, R.R., Cook, T.M., Gavini, C.K., White, C.R., Jones, J.R., Bovo, E., Zima, A.V., Brown, I.A., Dugas,
988 L.R., Zakharian, E., *et al.* (2020). Fecal transplantation and butyrate improve neuropathic pain, modify immune
989 cell profile, and gene expression in the PNS of obese mice. *Proc Natl Acad Sci U S A* *117*, 26482-26493.

- 990 Bulgart, H.R., Neczypor, E.W., Wold, L.E., and Mackos, A.R. (2020). Microbial involvement in Alzheimer
991 disease development and progression. *Mol Neurodegener* 15, 42.
- 992 Buysse, D.J., Reynolds, C.F., 3rd, Monk, T.H., Berman, S.R., and Kupfer, D.J. (1989). The Pittsburgh Sleep
993 Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 28, 193-213.
- 994 Callahan, B.J., McMurdie, P.J., Rosen, M.J., Han, A.W., Johnson, A.J., and Holmes, S.P. (2016). DADA2:
995 High-resolution sample inference from Illumina amplicon data. *Nat Methods* 13, 581-583.
- 996 Cani, P.D., Depommier, C., Derrien, M., Everard, A., and de Vos, W.M. (2022). Akkermansia muciniphila:
997 paradigm for next-generation beneficial microorganisms. *Nat Rev Gastroenterol Hepatol*.
- 998 Cartwright, N. (2011). A philosopher's view of the long road from RCTs to effectiveness. *Lancet* 377, 1400-
999 1401.
- 1000 Chandrasekaran, K., Salimian, M., Konduru, S.R., Choi, J., Kumar, P., Long, A., Klimova, N., Ho, C.Y.,
1001 Kristian, T., and Russell, J.W. (2019). Overexpression of Sirtuin 1 protein in neurons prevents and reverses
1002 experimental diabetic neuropathy. *Brain* 142, 3737-3752.
- 1003 Chaumeil, P.A., Mussig, A.J., Hugenholtz, P., and Parks, D.H. (2019). GTDB-Tk: a toolkit to classify genomes
1004 with the Genome Taxonomy Database. *Bioinformatics*.
- 1005 Chiu, W.T., Huang, S.J., Hwang, H.F., Tsauo, J.Y., Chen, C.F., Tsai, S.H., and Lin, M.R. (2006). Use of the
1006 WHOQOL-BREF for evaluating persons with traumatic brain injury. *J Neurotrauma* 23, 1609-1620.
- 1007 Claesson, M.J., Jeffery, I.B., Conde, S., Power, S.E., O'Connor, E.M., Cusack, S., Harris, H.M., Coakley, M.,
1008 Lakshminarayanan, B., O'Sullivan, O., *et al.* (2012). Gut microbiota composition correlates with diet and health
1009 in the elderly. *Nature* 488, 178-184.
- 1010 Cryan, J.F., O'Riordan, K.J., Sandhu, K., Peterson, V., and Dinan, T.G. (2020). The gut microbiome in
1011 neurological disorders. *Lancet Neurol* 19, 179-194.
- 1012 Dai, M., Liu, Y., Chen, W., Buch, H., Shan, Y., Chang, L., Bai, Y., Shen, C., Zhang, X., Huo, Y., *et al.* (2019).
1013 Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients. *Crit Care* 23,
1014 324.
- 1015 de Groot, P., Scheithauer, T., Bakker, G.J., Prodan, A., Levin, E., Khan, M.T., Herrema, H., Ackermans, M.,
1016 Serlie, M.J.M., de Brauw, M., *et al.* (2020). Donor metabolic characteristics drive effects of faecal microbiota
1017 transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. *Gut* 69, 502-512.
- 1018 Deng, X., Zhang, C., Wang, P., Wei, W., Shi, X., Wang, P., Yang, J., Wang, L., Tang, S., Fang, Y., *et al.* (2022).
1019 Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2
1020 diabetes. *J Clin Endocrinol Metab*.
- 1021 Derrien, M., Turrioni, F., Ventura, M., and van Sinderen, D. (2022). Insights into endogenous Bifidobacterium
1022 species in the human gut microbiota during adulthood. *Trends Microbiol*.
- 1023 Dewanjee, S., Das, S., Das, A.K., Bhattacharjee, N., Dihingia, A., Dua, T.K., Kalita, J., and Manna, P. (2018).
1024 Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. *Eur J Pharmacol* 833, 472-
1025 523.
- 1026 Ding, X., Li, Q., Li, P., Zhang, T., Cui, B., Ji, G., Lu, X., and Zhang, F. (2019). Long-Term Safety and Efficacy
1027 of Fecal Microbiota Transplant in Active Ulcerative Colitis. *Drug Saf* 42, 869-880.
- 1028 Dyck, P.J., Davies, J.L., Litchy, W.J., and O'Brien, P.C. (1997). Longitudinal assessment of diabetic
1029 polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. *Neurology* 49, 229-
1030 239.
- 1031 Fan, B., Li, C., Szalad, A., Wang, L., Pan, W., Zhang, R., Chopp, M., Zhang, Z.G., and Liu, X.S. (2020).
1032 Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes.
1033 *Diabetologia* 63, 431-443.
- 1034 Fang, Y., Zhang, C., Shi, H., Wei, W., Shang, J., Zheng, R., Yu, L., Wang, P., Yang, J., Deng, X., *et al.* (2021).
1035 Characteristics of the Gut Microbiota and Metabolism in Patients With Latent Autoimmune Diabetes in Adults:
1036 A Case-Control Study. *Diabetes Care* 44, 2738-2746.
- 1037 Feldman, E.L., Nave, K.A., Jensen, T.S., and Bennett, D.L.H. (2017). New Horizons in Diabetic Neuropathy:
1038 Mechanisms, Bioenergetics, and Pain. *Neuron* 93, 1296-1313.
- 1039 Forster, S.C., Kumar, N., Anonye, B.O., Almeida, A., Viciani, E., Stares, M.D., Dunn, M., Mkandawire, T.T.,
1040 Zhu, A., Shao, Y., *et al.* (2019). A human gut bacterial genome and culture collection for improved metagenomic
1041 analyses. *Nat Biotechnol* 37, 186-192.
- 1042 Fung, T.C., Olson, C.A., and Hsiao, E.Y. (2017). Interactions between the microbiota, immune and nervous
1043 systems in health and disease. *Nat Neurosci* 20, 145-155.
- 1044 Gomes, A.C., Hoffmann, C., and Mota, J.F. (2018). The human gut microbiota: Metabolism and perspective in
1045 obesity. *Gut Microbes* 9, 308-325.
- 1046 Goss, J.R., Goins, W.F., Lacomis, D., Mata, M., Glorioso, J.C., and Fink, D.J. (2002). Herpes simplex-mediated
1047 gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in
1048 the mouse. *Diabetes* 51, 2227-2232.

- 1049 Gylfadottir, S.S., Christensen, D.H., Nicolaisen, S.K., Andersen, H., Callaghan, B.C., Itani, M., Khan, K.S.,
1050 Kristensen, A.G., Nielsen, J.S., Sindrup, S.H., *et al.* (2020). Diabetic polyneuropathy and pain, prevalence, and
1051 patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2
1052 diabetes. *Pain* *161*, 574-583.
- 1053 Hanssen, N.M.J., de Vos, W.M., and Nieuwdorp, M. (2021). Fecal microbiota transplantation in human
1054 metabolic diseases: From a murky past to a bright future? *Cell Metab* *33*, 1098-1110.
- 1055 Herder, C., Kannenberg, J.M., Huth, C., Carstensen-Kirberg, M., Rathmann, W., Koenig, W., Heier, M.,
1056 Puttgen, S., Thorand, B., Peters, A., *et al.* (2017). Proinflammatory Cytokines Predict the Incidence and
1057 Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. *Diabetes Care* *40*, 569-576.
- 1058 Hicks, C.W., and Selvin, E. (2019). Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in
1059 Diabetes. *Curr Diab Rep* *19*, 86.
- 1060 Holvoet, T., Joossens, M., Vazquez-Castellanos, J.F., Christiaens, E., Heyerick, L., Boelens, J., Verhasselt, B.,
1061 van Vlierbergh, H., De Vos, M., Raes, J., *et al.* (2021). Fecal Microbiota Transplantation Reduces Symptoms in
1062 Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term
1063 Results From a Placebo-Controlled Randomized Trial. *Gastroenterology* *160*, 145-157 e148.
- 1064 Joly, A., Leulier, F., and De Vadder, F. (2021). Microbial Modulation of the Development and Physiology of the
1065 Enteric Nervous System. *Trends Microbiol* *29*, 686-699.
- 1066 Kang, D.D., Li, F., Kirton, E., Thomas, A., Egan, R., An, H., and Wang, Z. (2019). MetaBAT 2: an adaptive
1067 binning algorithm for robust and efficient genome reconstruction from metagenome assemblies. *PeerJ* *7*, e7359.
- 1068 Kim, J.E., Kim, H.E., Cho, H., Park, J.I., Kwak, M.J., Kim, B.Y., Yang, S.H., Lee, J.P., Kim, D.K., Joo, K.W., *et al.*
1069 *et al.* (2020). Effect of the similarity of gut microbiota composition between donor and recipient on graft function
1070 after living donor kidney transplantation. *Sci Rep* *10*, 18881.
- 1071 Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., and Glockner, F.O. (2013). Evaluation
1072 of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity
1073 studies. *Nucleic Acids Res* *41*, e1.
- 1074 Koh, A., De Vadder, F., Kovatcheva-Datchary, P., and Backhed, F. (2016). From Dietary Fiber to Host
1075 Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell* *165*, 1332-1345.
- 1076 Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat Methods* *9*, 357-359.
- 1077 Li, J., Zhang, H., Xie, M., Yan, L., Chen, J., and Wang, H. (2013). NSE, a potential biomarker, is closely
1078 connected to diabetic peripheral neuropathy. *Diabetes Care* *36*, 3405-3410.
- 1079 Li, Y., Lv, L., Ye, J., Fang, D., Shi, D., Wu, W., Wang, Q., Wu, J., Yang, L., Bian, X., *et al.* (2019).
1080 *Bifidobacterium adolescentis* CGMCC 15058 alleviates liver injury, enhances the intestinal barrier and modifies
1081 the gut microbiota in D-galactosamine-treated rats. *Appl Microbiol Biotechnol* *103*, 375-393.
- 1082 Liu, F., Li, J., Feng, G., and Li, Z. (2016). New Genomic Insights into "Entotheonella" Symbionts in *Theonella*
1083 *swinhoei*: Mixotrophy, Anaerobic Adaptation, Resilience, and Interaction. *Front Microbiol* *7*, 1333.
- 1084 Long, C., Yu, Y., Cui, B., Jagessar, S.A.R., Zhang, J., Ji, G., Huang, G., and Zhang, F. (2018). A novel quick
1085 transendoscopic enteral tubing in mid-gut: technique and training with video. *BMC Gastroenterol* *18*, 37.
- 1086 Lv, S.L., Fang, C., Hu, J., Huang, Y., Yang, B., Zou, R., Wang, F.Y., and Zhao, H.Q. (2015). Assessment of
1087 Peripheral Neuropathy Using Measurement of the Current Perception Threshold with the Neurometer(R) in
1088 patients with type 1 diabetes mellitus. *Diabetes Res Clin Pract* *109*, 130-134.
- 1089 Maioli, T.U., Borrás-Nogues, E., Torres, L., Barbosa, S.C., Martins, V.D., Langella, P., Azevedo, V.A., and
1090 Chatel, J.M. (2021). Possible Benefits of *Faecalibacterium prausnitzii* for Obesity-Associated Gut Disorders.
1091 *Front Pharmacol* *12*, 740636.
- 1092 Mallick, H., Rahnavard, A., McIver, L.J., Ma, S., Zhang, Y., Nguyen, L.H., Tickle, T.L., Weingart, G., Ren, B.,
1093 Schwager, E.H., *et al.* (2021). Multivariable association discovery in population-scale meta-omics studies. *PLoS*
1094 *Comput Biol* *17*, e1009442.
- 1095 McGregor, C.E., and English, A.W. (2018). The Role of BDNF in Peripheral Nerve Regeneration: Activity-
1096 Dependent Treatments and Val66Met. *Front Cell Neurosci* *12*, 522.
- 1097 Metwaly, A., Reitmeier, S., and Haller, D. (2022). Microbiome risk profiles as biomarkers for inflammatory and
1098 metabolic disorders. *Nat Rev Gastroenterol Hepatol* *19*, 383-397.
- 1099 Morais, L.H., Schreiber, H.L., and Mazmanian, S.K. (2020). The gut microbiota-brain axis in behaviour and
1100 brain disorders. *Nat Rev Microbiol*.
- 1101 Olesen, S.W., and Gerardin, Y. (2021). Re-Evaluating the Evidence for Faecal Microbiota Transplantation
1102 'Super-Donors' in Inflammatory Bowel Disease. *J Crohns Colitis* *15*, 453-461.
- 1103 Olm, M.R., Brown, C.T., Brooks, B., and Banfield, J.F. (2017). dRep: a tool for fast and accurate genomic
1104 comparisons that enables improved genome recovery from metagenomes through de-replication. *Isme j* *11*,
1105 2864-2868.
- 1106 Pan, F., Zhang, L., Li, M., Hu, Y., Zeng, B., Yuan, H., Zhao, L., and Zhang, C. (2018). Predominant gut
1107 *Lactobacillus murinus* strain mediates anti-inflammatory effects in calorie-restricted mice. *Microbiome* *6*, 54.

- 1108 Pane, K., Boccella, S., Guida, F., Franzese, M., Maione, S., and Salvatore, M. (2022). Role of gut microbiota in
1109 neuropathy and neuropathic pain states: A systematic preclinical review. *Neurobiol Dis* *170*, 105773.
1110 Parks, D.H., Imelfort, M., Skennerton, C.T., Hugenholtz, P., and Tyson, G.W. (2015). CheckM: assessing the
1111 quality of microbial genomes recovered from isolates, single cells, and metagenomes. *Genome Res* *25*, 1043-
1112 1055.
1113 Peng, Y., Leung, H.C., Yiu, S.M., and Chin, F.Y. (2012). IDBA-UD: a de novo assembler for single-cell and
1114 metagenomic sequencing data with highly uneven depth. *Bioinformatics* *28*, 1420-1428.
1115 Petersen, E.A., Stauss, T.G., Scowcroft, J.A., Brooks, E.S., White, J.L., Sills, S.M., Amirdelfan, K., Guirguis,
1116 M.N., Xu, J., Yu, C., *et al.* (2021). Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With
1117 Painful Diabetic Neuropathy: A Randomized Clinical Trial. *JAMA Neurol* *78*, 687-698.
1118 Pop-Busui, R., Boulton, A.J., Feldman, E.L., Bril, V., Freeman, R., Malik, R.A., Sosenko, J.M., and Ziegler, D.
1119 (2017). Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care* *40*,
1120 136-154.
1121 Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., and Glockner, F.O. (2013). The
1122 SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids*
1123 *Res* *41*, D590-596.
1124 Sanna, S., van Zuydam, N.R., Mahajan, A., Kurilshikov, A., Vich Vila, A., Vösa, U., Mujagic, Z., Masclee,
1125 A.A.M., Jonkers, D., Oosting, M., *et al.* (2019). Causal relationships among the gut microbiome, short-chain
1126 fatty acids and metabolic diseases. *Nat Genet* *51*, 600-605.
1127 Saxena, S., Carlson, D., Billington, R., and Life, W.G.W.H.O.Q.O. (2001). The WHO quality of life assessment
1128 instrument (WHOQOL-Bref): the importance of its items for cross-cultural research. *Qual Life Res* *10*, 711-721.
1129 Schlesinger, S., Herder, C., Kannenberg, J.M., Huth, C., Carstensen-Kirberg, M., Rathmann, W., Bonhof, G.J.,
1130 Koenig, W., Heier, M., Peters, A., *et al.* (2019). General and Abdominal Obesity and Incident Distal
1131 Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA
1132 F4/FF4 Cohort. *Diabetes Care* *42*, 240-247.
1133 Seemann, T. (2014). Prokka: rapid prokaryotic genome annotation. *Bioinformatics* *30*, 2068-2069.
1134 Shi, Y., Zhang, L., Do, K.A., Peterson, C.B., and Jenq, R. (2020). aPCoA: Covariate Adjusted Principal
1135 Coordinates Analysis. *Bioinformatics*.
1136 Slangen, R., Schaper, N.C., Faber, C.G., Joosten, E.A., Dirksen, C.D., van Dongen, R.T., Kessels, A.G., and van
1137 Kleef, M. (2014). Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective
1138 two-center randomized controlled trial. *Diabetes Care* *37*, 3016-3024.
1139 Sloan, G., Selvarajah, D., and Tesfaye, S. (2021). Pathogenesis, diagnosis and clinical management of diabetic
1140 sensorimotor peripheral neuropathy. *Nat Rev Endocrinol* *17*, 400-420.
1141 Sorboni, S.G., Moghaddam, H.S., Jafarzadeh-Esfehani, R., and Soleimanpour, S. (2022). A Comprehensive
1142 Review on the Role of the Gut Microbiome in Human Neurological Disorders. *Clin Microbiol Rev* *35*,
1143 e0033820.
1144 Tang, S.S., Liang, C.H., Liu, Y.L., Wei, W., Deng, X.R., Shi, X.Y., Wang, L.M., Zhang, L.J., and Yuan, H.J.
1145 (2022). Intermittent hypoxia is involved in gut microbial dysbiosis in type 2 diabetes mellitus and obstructive
1146 sleep apnea-hypopnea syndrome. *World journal of gastroenterology* *28*, 2320-2333.
1147 Tansey, M.G., Wallings, R.L., Houser, M.C., Herrick, M.K., Keating, C.E., and Joers, V. (2022). Inflammation
1148 and immune dysfunction in Parkinson disease. *Nat Rev Immunol*.
1149 Thevaranjan, N., Puchta, A., Schulz, C., Naidoo, A., Szamosi, J.C., Verschoor, C.P., Loukov, D., Schenck, L.P.,
1150 Jury, J., Foley, K.P., *et al.* (2017). Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability,
1151 Systemic Inflammation, and Macrophage Dysfunction. *Cell Host Microbe* *21*, 455-466 e454.
1152 Tilg, H., Zmora, N., Adolph, T.E., and Elinav, E. (2020). The intestinal microbiota fuelling metabolic
1153 inflammation. *Nat Rev Immunol* *20*, 40-54.
1154 Tirosh, A., Calay, E.S., Tuncman, G., Claiborn, K.C., Inouye, K.E., Eguchi, K., Alcalá, M., Rathaus, M.,
1155 Hollander, K.S., Ron, I., *et al.* (2019). The short-chain fatty acid propionate increases glucagon and FABP4
1156 production, impairing insulin action in mice and humans. *Sci Transl Med* *11*.
1157 Vincent, A.M., Calabek, B., Roberts, L., and Feldman, E.L. (2013). Biology of diabetic neuropathy. *Handb Clin*
1158 *Neurol* *115*, 591-606.
1159 Vital, M., Howe, A.C., and Tiedje, J.M. (2014). Revealing the bacterial butyrate synthesis pathways by
1160 analyzing (meta)genomic data. *mBio* *5*, e00889.
1161 Wang, Y., Ye, X., Ding, D., and Lu, Y. (2020). Characteristics of the intestinal flora in patients with peripheral
1162 neuropathy associated with type 2 diabetes. *J Int Med Res* *48*, 300060520936806.
1163 Waters, J.L., and Ley, R.E. (2019). The human gut bacteria Christensenellaceae are widespread, heritable, and
1164 associated with health. *BMC Biol* *17*, 83.
1165 Wu, G., Xu, T., Zhao, N., Lam, Y.Y., Ding, X., Wei, D., Fan, J., Shi, Y., Li, X., Li, M., *et al.* (2022). Two
1166 Competing Guilds as a Core Microbiome Signature for Chronic Diseases. *bioRxiv*, 2022.2005.2002.490290.

1167 Wu, G., Zhao, N., Zhang, C., Lam, Y.Y., and Zhao, L. (2021). Guild-based analysis for understanding gut
1168 microbiome in human health and diseases. *Genome Med* 13, 22.
1169 Xiao, S., Jiang, S., Qian, D., and Duan, J. (2020). Modulation of microbially derived short-chain fatty acids on
1170 intestinal homeostasis, metabolism, and neuropsychiatric disorder. *Appl Microbiol Biotechnol* 104, 589-601.
1171 Zhang, C., and Zhao, L. (2016). Strain-level dissection of the contribution of the gut microbiome to human
1172 metabolic disease. *Genome Med* 8, 41.
1173 Zhang, C.H., Lv, X., Du, W., Cheng, M.J., Liu, Y.P., Zhu, L., and Hao, J. (2019). The Akt/mTOR cascade
1174 mediates high glucose-induced reductions in BDNF via DNMT1 in Schwann cells in diabetic peripheral
1175 neuropathy. *Exp Cell Res* 383, 111502.
1176 Zhang, L., Liu, C., Jiang, Q., and Yin, Y. (2021). Butyrate in Energy Metabolism: There Is Still More to Learn.
1177 *Trends Endocrinol Metab* 32, 159-169.
1178 Zhang, T., Lu, G., Zhao, Z., Liu, Y., Shen, Q., Li, P., Chen, Y., Yin, H., Wang, H., Marcella, C., *et al.* (2020).
1179 Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies
1180 and in vitro screening. *Protein Cell* 11, 251-266.
1181 Zhao, C.G., Sun, W., Ju, F., Jiang, S., Wang, H., Sun, X.L., Mou, X., and Yuan, H. (2021). Analgesic Effects of
1182 Navigated Repetitive Transcranial Magnetic Stimulation in Patients With Acute Central Poststroke Pain. *Pain*
1183 *Ther* 10, 1085-1100.
1184 Zhao, L., Zhang, F., Ding, X., Wu, G., Lam, Y.Y., Wang, X., Fu, H., Xue, X., Lu, C., Ma, J., *et al.* (2018). Gut
1185 bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science* 359, 1151-1156.
1186

FIGURES

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

